Why should neuroscientists worry about iron? The emerging role of ferroptosis in the pathophysiology of neuroprogressive diseases

Behavioural Brain Research

Volumn 341, Issue , 2018, Pages 154-175

  Morris, Gerwyn ^a,b   Berk, Michael ^a,b   Carvalho, André F ^c   Maes, Michael ^a,d,e   Walker, Adam J ^a   Puri, Basant K ^f  

^a DEAKIN UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^d CHULALONGKORN UNIVERSITY   (Thailand)

^e MEDICAL UNIVERSITY OF PLOVDIV   (Bulgaria)

^f HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Ferroptosis; Glutathione and glutathione peroxidases; Iron homeostasis; Lipid peroxidation; Mitochondrial function; Oxidative and nitrosative stress

Indexed keywords

ACETYLCYSTEINE; CYSTEINE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE REDUCTASE; HEAT SHOCK PROTEIN 27; PHOSPHOLIPID HYDROPEROXIDE GLUTATHIONE PEROXIDASE; PROTEIN DEGLYCASE DJ-1; TRANSCRIPTION FACTOR NRF2; TRANSFERRIN; UBIDECARENONE; IRON;

ALZHEIMER DISEASE; ASTROCYTE; ENZYME INACTIVATION; ENZYME MECHANISM; ENZYME REGULATION; FERROPTOSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; IRON HOMEOSTASIS; IRON THERAPY; LIPID PEROXIDATION; MICROGLIA; MITOCHONDRION; NERVE CELL; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRECIPITATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CELL DEATH; METABOLISM; NEUROLOGIC DISEASE; PHYSIOLOGY;

ANIMALS; CELL DEATH; HUMANS; IRON; NERVOUS SYSTEM DISEASES;

EID: 85039994520     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2017.12.036     Document Type: Review

References (429)

1. Honig, L.S., Rosenberg, R.N., Apoptosis and neurologic disease. Am. J. Med. 108 (2000), 317–330.
2. Belaidi, A.A., Bush, A.I., Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics. J. Neurochem. 139:Suppl. 1 (2016), 179–197.
3. Do Van, B., Gouel, F., Jonneaux, A., Timmerman, K., Gele, P., Petrault, M., Bastide, M., Laloux, C., Moreau, C., Bordet, R., Devos, D., Devedjian, J.C., Ferroptosis, a newly characterized form of cell death in Parkinson's disease that is regulated by PKC. Neurobiol. Dis. 94 (2016), 169–178.
4. Guiney, S.J., Adlard, P.A., Bush, A.I., Finkelstein, D.I., Ayton, S., Ferroptosis and cell death mechanisms in Parkinson's disease. Neurochem. Int. 104 (2017), 34–48.
5. Andreazza, A.C., Gildengers, A., Rajji, T.K., Zuzarte, P.M.L., Mulsant, B.H., Young, L.T., Oxidative stress in older patients with Bipolar Disorder. Am. J. Geriatr Psychiatry 23 (2015), 314–319.
6. Wang, J., Shao, L., Sun, X., Young, L., Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord. 11 (2009), 523–529.
7. Medina-Hernández, V., Ramos-Loyo, J., Luquin, S., Sánchez, L.F.C., García-Estrada, J., Navarro-Ruiz, A., Increased lipid peroxidation and neuron specific enolase in treatment refractory schizophrenics. J. Psychiatr. Res. 41 (2007), 652–658.
8. Ramos-Loyo, J., Medina-Hernández, V., Estarrón-Espinosa, M., Canales-Aguirre, A., Gómez-Pinedo, U., Cerdán-Sánchez, L.F., Sex differences in lipid peroxidation and fatty acid levels in recent onset schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 44 (2013), 154–161.
9. Selley, M.L., Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression. J. Affect. Disord. 80 (2004), 249–256.
10. Romano, A., Serviddio, G., Calcagnini, S., Villani, R., Giudetti, A.M., Cassano, T., Gaetani, S., Linking lipid peroxidation and neuropsychiatric disorders: focus on 4-hydroxy-2-nonenal. Free Radical Bio. Med. 111 (2017), 281–293.
11. Dixon, S.J., Lemberg, K.M., Lamprecht, M.R., Skouta, R., Zaitsev, E.M., Gleason, C.E., Patel, D.N., Bauer, A.J., Cantley, A.M., Yang, W.S., Morrison, B. 3rd, Stockwell, B.R., Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149 (2012), 1060–1072.
12. Yang, W.S., Kim, K.J., Gaschler, M.M., Patel, M., Shchepinov, M.S., Stockwell, B.R., Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc. Natl. Acad. Sci. 113 (2016), E4966–E4975.
13. Yang, W.S., SriRamaratnam, R., Welsch, M.E., Shimada, K., Skouta, R., Viswanathan, V.S., Cheah, J.H., Clemons, P.A., Shamji, A.F., Clish, C.B., Brown, L.M., Girotti, A.W., Cornish, V.W., Schreiber, S.L., Stockwell, B.R., Regulation of ferroptotic cancer cell death by GPX4. Cell 156 (2014), 317–331.
14. Gao, M., Monian, P., Quadri, N., Ramasamy, R., Jiang, X., Glutaminolysis and transferrin regulate ferroptosis. Mol. Cell 59 (2015), 298–308.
15. Wang, S.J., Li, D., Ou, Y., Jiang, L., Chen, Y., Zhao, Y., Gu, W., Acetylation is crucial for p53-mediated ferroptosis and tumor suppression. Cell Rep. 17 (2016), 366–373.
16. Hou, W., Xie, Y., Song, X., Sun, X., Lotze, M.T., Zeh, H.J. 3rd, Kang, R., Tang, D., Autophagy promotes ferroptosis by degradation of ferritin. Autophagy 12 (2016), 1425–1428.
17. Torii, S., Shintoku, R., Kubota, C., Yaegashi, M., Torii, R., Sasaki, M., Suzuki, T., Mori, M., Yoshimoto, Y., Takeuchi, T., Yamada, K., An essential role for functional lysosomes in ferroptosis of cancer cells. Biochem. J. 473 (2016), 769–777.
18. Gao, M., Monian, P., Pan, Q., Zhang, W., Xiang, J., Jiang, X., Ferroptosis is an autophagic cell death process. Cell Res. 26 (2016), 1021–1032.
19. Latunde-Dada, G.O., Ferroptosis: role of lipid peroxidation, iron and ferritinophagy. Biochim. Biophys. Acta 1861 (2017), 1893–1900.
20. Mancias, J.D., Wang, X., Gygi, S.P., Harper, J.W., Kimmelman, A.C., Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature 509 (2014), 105–109.
21. Cao, J.Y., Dixon, S.J., Mechanisms of ferroptosis. Cell. Mol. Life Sci. 73 (2016), 2195–2209.
22. Yu, H., Guo, P., Xie, X., Wang, Y., Chen, G., Ferroptosis, a new form of cell death, and its relationships with tumourous diseases. J. Cell Mol. Med. 21 (2017), 648–657.
23. Xie, Y., Hou, W., Song, X., Yu, Y., Huang, J., Sun, X., Kang, R., Tang, D., Ferroptosis: process and function. Cell Death Differ. 23 (2016), 369–379.
24. Krainz, T., Gaschler, M.M., Lim, C., Sacher, J.R., Stockwell, B.R., Wipf, P., A mitochondrial-targeted nitroxide is a potent inhibitor of ferroptosis. ACS Cent. Sci. 2 (2016), 653–659.
25. Neitemeier, S., Jelinek, A., Laino, V., Hoffmann, L., Eisenbach, I., Eying, R., Ganjam, G.K., Dolga, A.M., Oppermann, S., Culmsee, C., BID links ferroptosis to mitochondrial cell death pathways. Redox Biol. 12 (2017), 558–570.
26. Jin, L., Alesi, G.N., Kang, S., Glutaminolysis as a target for cancer therapy. Oncogene 35 (2016), 3619–3625.
27. Eng, C.H., Yu, K., Lucas, J., White, E., Abraham, R.T., Ammonia derived from glutaminolysis is a diffusible regulator of autophagy. Sci. Signal., 3, 2010, ra31.
28. Polletta, L., Vernucci, E., Carnevale, I., Arcangeli, T., Rotili, D., Palmerio, S., Steegborn, C., Nowak, T., Schutkowski, M., Pellegrini, L., Sansone, L., Villanova, L., Runci, A., Pucci, B., Morgante, E., Fini, M., Mai, A., Russo, M.A., Tafani, M., SIRT5 regulation of ammonia-induced autophagy and mitophagy. Autophagy 11 (2015), 253–270.
29. D'Herde, K., Krysko, D.V., Ferroptosis: oxidized PEs trigger death. Nat. Chem. Biol. 13 (2017), 4–5.
30. Kagan, V.E., Mao, G., Qu, F., Angeli, J.P.F., Doll, S., Croix, C.S., Dar, H.H., Liu, B., Tyurin, V.A., Ritov, V.B., Kapralov, A.A., Amoscato, A.A., Jiang, J., Anthonymuthu, T., Mohammadyani, D., Yang, Q., Proneth, B., Klein-Seetharaman, J., Watkins, S., Bahar, I., Greenberger, J., Mallampalli, R.K., Stockwell, B.R., Tyurina, Y.Y., Conrad, M., Bayir, H., Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat. Chem. Biol. 13 (2017), 81–90.
31. Doll, S., Proneth, B., Tyurina, Y.Y., Panzilius, E., Kobayashi, S., Ingold, I., Irmler, M., Beckers, J., Aichler, M., Walch, A., Prokisch, H., Trumbach, D., Mao, G., Qu, F., Bayir, H., Fullekrug, J., Scheel, C.H., Wurst, W., Schick, J.A., Kagan, V.E., Angeli, J.P.F., Conrad, M., ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol. 13 (2017), 91–98.
32. Dixon, S.J., Stockwell, B.R., The role of iron and reactive oxygen species in cell death. Nat. Chem. Biol. 10 (2014), 9–17.
33. Sun, X., Ou, Z., Chen, R., Niu, X., Chen, D., Kang, R., Tang, D., Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology (Baltimore, Md.) 63 (2016), 173–184.
34. Andrews, N.C., Schmidt, P.J., Iron homeostasis. Annu. Rev. Physiol. 69 (2007), 69–85.
35. Kwon, M.Y., Park, E., Lee, S.J., Chung, S.W., Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death. Oncotarget 6 (2015), 24393–24403.
36. Bresgen, N., Eckl, P.M., Oxidative stress and the homeodynamics of iron metabolism. Biomolecules 5 (2015), 808–847.
37. Lucas, K., Morris, G., Anderson, G., Maes, M., The toll-like receptor radical cycle pathway: a new drug target in immune-related chronic fatigue. CNS Neurol. Disord. Drug Targets 14 (2015), 838–854.
38. Morris, G., Berk, M., The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders. BMC Med., 13, 2015, 68.
39. Morris, G., Berk, M., Walder, K., Maes, M., Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses. BMC Med., 13, 2015, 28.
40. Circu, M.L., Aw, T.Y., Reactive oxygen species, cellular redox systems and apoptosis. Free. Radic. Biol.Med. 48 (2010), 749–762.
41. Morris, G., Walder, K., Puri, B.K., Berk, M., Maes, M., The deleterious effects of oxidative and nitrosative stress on palmitoylation, membrane lipid rafts and lipid-based cellular signalling: new drug targets in neuroimmune disorders. Mol. Neurobiol 53 (2016), 4638–4658.
42. Nakamura, T., Tu, S., Akhtar, M.W., Sunico, C.R., Okamoto, S., Lipton, S.A., Aberrant protein s-nitrosylation in neurodegenerative diseases. Neuron 78 (2013), 596–614.
43. Friedmann Angeli, J.P., Schneider, M., Proneth, B., Tyurina, Y.Y., Tyurin, V.A., Hammond, V.J., Herbach, N., Aichler, M., Walch, A., Eggenhofer, E., Basavarajappa, D., Radmark, O., Kobayashi, S., Seibt, T., Beck, H., Neff, F., Esposito, I., Wanke, R., Forster, H., Yefremova, O., Heinrichmeyer, M., Bornkamm, G.W., Geissler, E.K., Thomas, S.B., Stockwell, B.R., O'Donnell, V.B., Kagan, V.E., Schick, J.A., Conrad, M., Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 16 (2014), 1180–1191.
44. Linkermann, A., Hackl, M.J., Kunzendorf, U., Walczak, H., Krautwald, S., Jevnikar, A.M., Necroptosis in immunity and ischemia-reperfusion injury. Am. J. Transplant. 13 (2013), 2797–2804.
45. Martin-Sanchez, D., Ruiz-Andres, O., Poveda, J., Carrasco, S., Cannata-Ortiz, P., Sanchez-Niño, M.D., Ruiz Ortega, M., Egido, J., Linkermann, A., Ortiz, A., Sanz, A.B., Ferroptosis, but not necroptosis, is important in nephrotoxic folic acid–induced AKI. J. Am. Soc. Nephrol. 28 (2017), 218–229.
46. Stockwell, B.R., Friedmann Angeli, J.P., Bayir, H., Bush, A.I., Conrad, M., Dixon, S.J., Fulda, S., Gascon, S., Hatzios, S.K., Kagan, V.E., Noel, K., Jiang, X., Linkermann, A., Murphy, M.E., Overholtzer, M., Oyagi, A., Pagnussat, G.C., Park, J., Ran, Q., Rosenfeld, C.S., Salnikow, K., Tang, D., Torti, F.M., Torti, S.V., Toyokuni, S., Woerpel, K.A., Zhang, D.D., Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171 (2017), 273–285.
47. Faux, N.G., Rembach, A., Wiley, J., Ellis, K.A., Ames, D., Fowler, C.J., Martins, R.N., Pertile, K.K., Rumble, R.L., Trounson, B., Masters, C.L., Bush, A.I., An anemia of Alzheimer's disease. Mol. Psychiatry 19 (2014), 1227–1234.
48. Gangania, M.K., Batra, J., Kushwaha, S., Agarwal, R., Role of iron and copper in the pathogenesis of Parkinson's disease. Indian J. Clinical Biochem.: IJCB 32 (2017), 353–356.
49. Camaschella, C., Iron and hepcidin: a story of recycling and balance. Hematol. Am. Soc. Hematol. Educ. Program(2013), 2013, 1–8.
50. Ganz, T., Nemeth, E., Hepcidin and iron homeostasis. Biochim. Biophys. Acta 1823 (2012), 1434–1443.
51. Ganz, T., Nemeth, E., Iron homeostasis in host defence and inflammation. Nat. Rev. Immunol. 15 (2015), 500–510.
52. Kasvosve, I., Effect of ferroportin polymorphism on iron homeostasis and infection. Clin. Chim. Acta 416 (2013), 20–25.
53. Nemeth, E., Ganz, T., The role of hepcidin in iron metabolism. Acta Haematologica 122 (2009), 78–86.
54. Nemeth, E., Tuttle, M.S., Powelson, J., Vaughn, M.B., Donovan, A., Ward, D.M., Ganz, T., Kaplan, J., Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science (New York, N.Y.) 306 (2004), 2090–2093.
55. Drakesmith, H., Nemeth, E., Ganz, T., Ironing out ferroportin. Cell Metab 22 (2015), 777–787.
56. Millonig, G., Ganzleben, I., Peccerella, T., Casanovas, G., Brodziak-Jarosz, L., Breitkopf-Heinlein, K., Dick, T.P., Seitz, H.K., Muckenthaler, M.U., Mueller, S., Sustained submicromolar H2O2 levels induce hepcidin via signal transducer and activator of transcription 3 (STAT3). The Journal of biological chemistry 287 (2012), 37472–37482.
57. Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B.K., Ganz, T., IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. The Journal of clinical investigation 113 (2004), 1271–1276.
58. Pietrangelo, A., Dierssen, U., Valli, L., Garuti, C., Rump, A., Corradini, E., Ernst, M., Klein, C., Trautwein, C., STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology 132 (2007), 294–300.
59. Verga, Falzacappa M.V., Vujic Spasic, M., Kessler, R., Stolte, J., Hentze, M.W., Muckenthaler, M.U., STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 109 (2007), 353–358.
60. Wrighting, D.M., Andrews, N.C., Interleukin-6 induces hepcidin expression through STAT3. Blood 108 (2006), 3204–3209.
61. Silva, B., Faustino, P., An overview of molecular basis of iron metabolism regulation and the associated pathologies. Biochim. Biophys. Acta 1852 (2015), 1347–1359.
62. Laftah, A.H., Latunde-Dada, G.O., Fakih, S., Hider, R.C., Simpson, R.J., McKie, A.T., Haem and folate transport by proton-coupled folate transporter/haem carrier protein 1 (SLC46A1). Br. J. Nutr. 101 (2008), 1150–1156.
63. Mastrogiannaki, M., Matak, P., Peyssonnaux, C., The gut in iron homeostasis: role of HIF-2 under normal and pathological conditions. Blood 122 (2013), 885–892.
64. Bao, G., Clifton, M., Hoette, T.M., Mori, K., Deng, S.-X., Qiu, A., Viltard, M., Williams, D., Paragas, N., Leete, T., Kulkarni, R., Li, X., Lee, B., Kalandadze, A., Ratner, A.J., Pizarro, J.C., Schmidt-Ott, K.M., Landry, D.W., Raymond, K.N., Strong, R.K., Barasch, J., Iron traffics in circulation bound to a siderocalin (Ngal)-catechol complex. Nat. Chem. Biol. 6 (2010), 602–609.
65. MacKenzie, E.L., Iwasaki, K., Tsuji, Y., Intracellular iron transport and storage: from molecular mechanisms to health implications. Antioxid. Redox Signal. 10 (2008), 997–1030.
66. Garrick, M.D., Garrick, L.M., Cellular iron transport. Biochim. Biophys. Acta 1790 (2009), 309–325.
67. Horowitz, M.P., Greenamyre, J.T., Mitochondrial iron metabolism and its role in neurodegeneration. J. Alzheimers Dis. 20 (2010), S551–S568.
68. Arosio, P., Levi, S., Cytosolic and mitochondrial ferritins in the regulation of cellular iron homeostasis and oxidative damage. Biochim. Biophys. Acta 1800 (2010), 783–792.
69. Zhao, G., Arosio, P., Chasteen, N.D., Iron(II) and hydrogen peroxide detoxification by human H-chain ferritin. An EPR spin-trapping study. Biochemistry 45 (2006), 3429–3436.
70. Argaw, A., Zhang, Y., Snyder, B., Zhao, M., Kopp, N., Lee, S., Raine, C., Brosnan, C., John, G., IL-1beta regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program. J. Immunol. 177 (2006), 5574–5584.
71. Zhang, Y., Mikhael, M., Xu, D., Li, Y., Soe-Lin, S., Ning, B., Li, W., Nie, G., Zhao, Y., Ponka, P., Lysosomal proteolysis is the primary degradation pathway for cytosolic ferritin and cytosolic ferritin degradation is necessary for iron exit. Antioxid. Redox Signal. 13 (2010), 999–1009.
72. Stehling, O., Wilbrecht, C., Lill, R., Mitochondrial iron-sulfur protein biogenesis and human disease. Biochimie 100 (2014), 61–77.
73. Stehling, O., Lill, R., The role of mitochondria in cellular iron–sulfur protein biogenesis: mechanisms, connected processes, and diseases. Cold Spring Harb. Perspect. Biol., 5, 2013, a011312.
74. Paradkar, P.N., Zumbrennen, K.B., Paw, B.H., Ward, D.M., Kaplan, J., Regulation of mitochondrial iron import through differential turnover of mitoferrin 1 and mitoferrin 2. Mol. Cell. Biol. 29 (2009), 1007–1016.
75. Rouault, T.A., Mitochondrial iron overload: causes and consequences. Curr. Opin. Genet. Dev. 38 (2016), 31–37.
76. Martelli, A., Schmucker, S., Reutenauer, L., Mathieu, J.R., Peyssonnaux, C., Karim, Z., Puy, H., Galy, B., Hentze, M.W., Puccio, H., Iron regulatory protein 1 sustains mitochondrial iron loading and function in frataxin deficiency. Cell Metab. 21 (2015), 311–322.
77. Bencze, K.Z., Yoon, T., Millan-Pacheco, C., Bradley, P.B., Pastor, N., Cowan, J.A., Stemmler, T.L., Human frataxin: iron and ferrochelatase binding surface. Chem. Commun. (Cambridge, England), 2007, 1798–1800.
78. Tsai, C.L., Barondeau, D.P., Human frataxin is an allosteric switch that activates the Fe-S cluster biosynthetic complex. Biochemistry 49 (2010), 9132–9139.
79. Lefevre, S., Sliwa, D., Rustin, P., Camadro, J.M., Santos, R., Oxidative stress induces mitochondrial fragmentation in frataxin-deficient cells. Biochem. Biophys. Res. Commun. 418 (2012), 336–341.
80. Bou-Abdallah, F., Santambrogio, P., Levi, S., Arosio, P., Chasteen, N.D., Unique iron binding and oxidation properties of human mitochondrial ferritin: a comparative analysis with human H-chain ferritin. J. Mol. Biol. 347 (2005), 543–554.
81. Gao, G., Chang, Y.Z., Mitochondrial ferritin in the regulation of brain iron homeostasis and neurodegenerative diseases. Front. Pharmacol., 5, 2014, 19.
82. Nie, G., Sheftel, A.D., Kim, S.F., Ponka, P., Overexpression of mitochondrial ferritin causes cytosolic iron depletion and changes cellular iron homeostasis. Blood 105 (2005), 2161–2167.
83. Moos, T., Rosengren Nielsen, T., Skjorringe, T., Morgan, E.H., Iron trafficking inside the brain. J. Neurochem. 103 (2007), 1730–1740.
84. Rouault, T.A., Zhang, D.-L., Jeong, S.Y., Brain iron homeostasis, the choroid plexus, and localization of iron transport proteins. Metab. Brain Dis. 24 (2009), 673–684.
85. Simpson, I.A., Ponnuru, P., Klinger, M.E., Myers, R.L., Devraj, K., Coe, C.L., Lubach, G.R., Carruthers, A., Connor, J.R., A novel model for brain iron uptake: introducing the concept of regulation. J. Cereb. Blood Flow Metab. 35 (2015), 48–57.
86. McCarthy, R.C., Kosman, D.J., Glial cell ceruloplasmin and hepcidin differentially regulate iron efflux from brain microvascular endothelial cells. PloS One, 9, 2014, e89003.
87. McCarthy, R.C., Kosman, D.J., Iron transport across the blood-brain barrier: development, neurovascular regulation and cerebral amyloid angiopathy. Cell. Mol. Life Sci.: CMLS 72 (2015), 709–727.
88. Codazzi, F., Pelizzoni, I., Zacchetti, D., Grohovaz, F., Iron entry in neurons and astrocytes: a link with synaptic activity. Front. Mol. Neurosci., 8, 2015.
89. Mills, E., Dong, X.-p, Wang, F., Xu, H., Mechanisms of brain iron transport: insight into neurodegeneration and CNS disorders. Future Med. Chem., 2, 2010, 51.
90. Ji, C., Kosman, D.J., Molecular mechanisms of non-transferrin-bound and transferring-bound iron uptake in primary hippocampal neurons. J. Neurochem. 133 (2015), 668–683.
91. Hohnholt, M.C., Dringen, R., Uptake and metabolism of iron and iron oxide nanoparticles in brain astrocytes. Biochem. Soc. Trans. 41 (2013), 1588–1592.
92. Pelizzoni, I., Zacchetti, D., Campanella, A., Grohovaz, F., Codazzi, F., Iron uptake in quiescent and inflammation-activated astrocytes: a potentially neuroprotective control of iron burden. Biochim. Biophys. Acta 1832 (2013), 1326–1333.
93. Liu, Z., Shen, H.C., Lian, T.H., Mao, L., Tang, S.X., Sun, L., Huang, X.Y., Guo, P., Cao, C.J., Yu, S.Y., Zuo, L.J., Wang, X.M., Chen, S.D., Chan, P., Zhang, W., Iron deposition in substantia nigra: abnormal iron metabolism, neuroinflammatory mechanism and clinical relevance. Sci. Rep., 7, 2017, 14973.
94. Zhang, F., Tao, Y., Zhang, Z., Guo, X., An, P., Shen, Y., Wu, Q., Yu, Y., Wang, F., Metalloreductase Steap3 coordinates the regulation of iron homeostasis and inflammatory responses. Haematologica 97 (2012), 1826–1835.
95. Anderson, G.J., Frazer, D.M., Current understanding of iron homeostasis. Am. J. Clin. Nutr. 106:Suppl 6 (2017), 1559S–1566S.
96. Skjorringe, T., Burkhart, A., Johnsen, K.B., Moos, T., Divalent metal transporter 1 (DMT1) in the brain: implications for a role in iron transport at the blood-brain barrier, and neuronal and glial pathology. Front. Mol. Neurosci., 8, 2015, 19.
97. Richardson, D.R., Morgan, E.H., The transferrin homologue, melanotransferrin (p97), is rapidly catabolized by the liver of the rat and does not effectively donate iron to the brain. Biochim. Biophys. Acta 1690 (2004), 124–133.
98. Musci, G., Polticelli, F., Bonaccorsi di Patti, M.C., Ceruloplasmin-ferroportin system of iron traffic in vertebrates. World J. Biol. Chem. 5 (2014), 204–215.
99. Vashchenko, G., MacGillivray, R.T., Multi-copper oxidases and human iron metabolism. Nutrients 5 (2013), 2289–2313.
100. Singh, N., Haldar, S., Tripathi, A.K., Horback, K., Wong, J., Sharma, D., Beserra, A., Suda, S., Anbalagan, C., Dev, S., Mukhopadhyay, C.K., Singh, A., Brain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunities. Antioxid. Redox Signal. 20 (2014), 1324–1363.
101. Urrutia, P., Aguirre, P., Esparza, A., Tapia, V., Mena, N.P., Arredondo, M., Gonzalez-Billault, C., Nunez, M.T., Inflammation alters the expression of DMT1, FPN1 and hepcidin, and it causes iron accumulation in central nervous system cells. J. Neurochem. 126 (2013), 541–549.
102. Pelizzoni, I., Macco, R., Morini, M.F., Zacchetti, D., Grohovaz, F., Codazzi, F., Iron handling in hippocampal neurons: activity-dependent iron entry and mitochondria-mediated neurotoxicity. Aging Cell 10 (2011), 172–183.
103. Pelizzoni, I., Zacchetti, D., Smith, C.P., Grohovaz, F., Codazzi, F., Expression of divalent metal transporter 1 in primary hippocampal neurons: reconsidering its role in non-transferrin-bound iron influx. J. Neurochem. 120 (2012), 269–278.
104. Li, M.-H., Inoue, K., Si, H.-F., Xiong, Z.-G., Calcium-permeable ion channels involved in glutamate receptor-independent ischemic brain injury. Acta Pharmacol. Sinica 32 (2011), 734–740.
105. Hentze, M.W., Muckenthaler, M.U., Galy, B., Camaschella, C., Two to tango: regulation of mammalian iron metabolism. Cell 142 (2010), 24–38.
106. Chen, Y., Khan, R.S., Cwanger, A., Song, Y., Steenstra, C., Bang, S., Cheah, J.H., Dunaief, J., Shindler, K.S., Snyder, S.H., Kim, S.F., Dexras1, a small GTPase, is required for glutamate-NMDA neurotoxicity. J. Neurosci. 33 (2013), 3582–3587.
107. Huang, E., Ong, W.Y., Go, M.L., Connor, J.R., Upregulation of iron regulatory proteins and divalent metal transporter-1 isoforms in the rat hippocampus after kainate induced neuronal injury. Exp. Brain Res. 170 (2006), 376–386.
108. Wang, X., Michaelis, E., Selective neuronal vulnerability to oxidative stress in the brain. Front. Aging Neurosci., 2, 2010.
109. Rathore, K.I., Redensek, A., David, S., Iron homeostasis in astrocytes and microglia is differentially regulated by TNF-alpha and TGF-beta1. Glia 60 (2012), 738–750.
110. Wong, A.D., Ye, M., Levy, A.F., Rothstein, J.D., Bergles, D.E., Searson, P.C., The blood-brain barrier: an engineering perspective. Front. Neuroeng., 6, 2013, 7.
111. Qian, Z.M., He, X., Liang, T., Wu, K.C., Yan, Y.C., Lu, L.N., Yang, G., Luo, Q.Q., Yung, W.H., Ke, Y., Lipopolysaccharides upregulate hepcidin in neuron via microglia and the IL-6/STAT3 signaling pathway. Mol. Neurobiol. 50 (2014), 811–820.
112. You, L.-H., Yan, C.-Z., Zheng, B.-J., Ci, Y.-Z., Chang, S.-Y., Yu, P., Gao, G.-F., Li, H.-Y., Dong, T.-Y., Chang, Y.-Z., Astrocyte hepcidin is a key factor in LPS-induced neuronal apoptosis. Cell. Death Dis., 8, 2017, e2676.
113. Anderson, C.P., Shen, M., Eisenstein, R.S., Leibold, E.A., Mammalian iron metabolism and its control by iron regulatory proteins. Biochim. Biophys. Acta 1823 (2012), 1468–1483.
114. Zhang, D.-L., Ghosh, M.C., Rouault, T.A., The physiological functions of iron regulatory proteins in iron homeostasis - an update. Front. Pharmacol., 5, 2014.
115. Rouault, T.A., The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat. Chem. Biol. 2 (2006), 406–414.
116. Bornsen, L., Romme Christensen, J., Ratzer, R., Hedegaard, C., Sondergaard, H.B., Krakauer, M., Hesse, D., Nielsen, C.H., Sorensen, P.S., Sellebjerg, F., Endogenous interferon-beta-inducible gene expression and interferon-beta-treatment are associated with reduced T cell responses to myelin basic protein in multiple sclerosis. PloS One, 10, 2015, e0118830.
117. Caltagirone, A., Weiss, G., Pantopoulos, K., Modulation of cellular iron metabolism by hydrogen peroxide. Effects of H2O2 on the expression and function of iron-responsive element-containing mRNAs in B6 fibroblasts. J. Biol. Chem. 276 (2001), 19738–19745.
118. Eisenstein, R.S., Ross, K.L., Novel roles for iron regulatory proteins in the adaptive response to iron deficiency. J. Nutr. 133 (2003), 1510s–1516s.
119. Pantopoulos, K., Hentze, M.W., Rapid responses to oxidative stress mediated by iron regulatory protein. EMBO J. 14 (1995), 2917–2924.
120. Chen, O.S., Schalinske, K.L., Eisenstein, R.S., Dietary iron intake modulates the activity of iron regulatory proteins and the abundance of ferritin and mitochondrial aconitase in rat liver. J. Nutr. 127 (1997), 238–248.
121. Meyron-Holtz, E.G., Ghosh, M.C., Rouault, T.A., Mammalian tissue oxygen levels modulate iron-regulatory protein activities in vivo. Science (New York, N.Y.) 306 (2004), 2087–2090.
122. Stys, A., Galy, B., Starzynski, R.R., Smuda, E., Drapier, J.C., Lipinski, P., Bouton, C., Iron regulatory protein 1 outcompetes iron regulatory protein 2 in regulating cellular iron homeostasis in response to nitric oxide. J. Biol. Chem. 286 (2011), 22846–22854.
123. Yuan, H., Li, X., Zhang, X., Kang, R., Tang, D., Identification of ACSL4 as a biomarker and contributor of ferroptosis. Biochem. Biophys. Res. Commun. 478 (2016), 1338–1343.
124. Kim, S., Ponka, P., Nitric oxide-mediated modulation of iron regulatory proteins: implication for cellular iron homeostasis. Blood Cells Mol. Dis. 29 (2002), 400–410.
125. Mikhael, M., Kim, S.F., Schranzhofer, M., Soe-Lin, S., Sheftel, A.D., Mullner, E.W., Ponka, P., Iron regulatory protein-independent regulation of ferritin synthesis by nitrogen monoxide. FEBS J. 273 (2006), 3828–3836.
126. Cairo, G., Ronchi, R., Recalcati, S., Campanella, A., Minotti, G., Nitric oxide and peroxynitrite activate the iron regulatory protein-1 of J774A.1 macrophages by direct disassembly of the Fe-S cluster of cytoplasmic aconitase. Biochemistry 41 (2002), 7435–7442.
127. Soum, E., Brazzolotto, X., Goussias, C., Bouton, C., Moulis, J.M., Mattioli, T.A., Drapier, J.C., Peroxynitrite and nitric oxide differently target the iron-sulfur cluster and amino acid residues of human iron regulatory protein 1. Biochemistry 42 (2003), 7648–7654.
128. Conrad, M., Sato, H., The oxidative stress-inducible cystine/glutamate antiporter, system x (c) (-) : cystine supplier and beyond. Amino Acids 42 (2012), 231–246.
129. Lall, M.M., Ferrell, J., Nagar, S., Fleisher, L.N., McGahan, M.C., Iron regulates L-cystine uptake and glutathione levels in lens epithelial and retinal pigment epithelial cells by its effect on cytosolic aconitase. Invest. Ophthalmol. Vis. Sci. 49 (2008), 310–319.
130. Gorrini, C., Harris, I.S., Mak, T.W., Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Dis. 12 (2013), 931–947.
131. Pietsch, E.C., Chan, J.Y., Torti, F.M., Torti, S.V., Nrf2 mediates the induction of ferritin H in response to xenobiotics and cancer chemopreventive dithiolethiones. J. Biol. Chem. 278 (2003), 2361–2369.
132. Tran, T.N., Eubanks, S.K., Schaffer, K.J., Zhou, C.Y., Linder, M.C., Secretion of ferritin by rat hepatoma cells and its regulation by inflammatory cytokines and iron. Blood 90 (1997), 4979–4986.
133. Maria, T.G., Vasileios, K.E., Panagiotis, P.S., Kostas, S.N., Changes of acute-phase protein levels in the serum of lung cancer patients following radiotherapy. Int. J. Clin. Exp. Med. 6 (2013), 50–56.
134. Kalgaonkar, S., Lonnerdal, B., Receptor-mediated uptake of ferritin-bound iron by human intestinal Caco-2 cells. J. Nutr. Biochem. 20 (2009), 304–311.
135. Li, L., Fang, C.J., Ryan, J.C., Niemi, E.C., Lebron, J.A., Bjorkman, P.J., Arase, H., Torti, F.M., Torti, S.V., Nakamura, M.C., Seaman, W.E., Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 3505–3510.
136. Watanabe, K., Yamashita, Y., Ohgawara, H., Sekiguchi, M., Satake, N., Orino, K., Yamamoto, S., Iron content of rat serum ferritin. J. Vet. Med. Sci. 63 (2001), 587–589.
137. Hintze, K.J., Theil, E.C., DNA and mRNA elements with complementary responses to hemin, antioxidant inducers, and iron control ferritin-L expression. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 15048–15052.
138. Vile, G.F., Basu-Modak, S., Waltner, C., Tyrrell, R.M., Heme oxygenase 1 mediates an adaptive response to oxidative stress in human skin fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 91 (1994), 2607–2610.
139. Vile, G.F., Tyrrell, R.M., Oxidative stress resulting from ultraviolet A irradiation of human skin fibroblasts leads to a heme oxygenase-dependent increase in ferritin. J. Biol. Chem. 268 (1993), 14678–14681.
140. Boyle, J.J., Johns, M., Lo, J., Chiodini, A., Ambrose, N., Evans, P.C., Mason, J.C., Haskard, D.O., Heme induces heme oxygenase 1 via Nrf2: role in the homeostatic macrophage response to intraplaque hemorrhage. Arterioscler. Thromb. Vasc. Biol. 31 (2011), 2685–2691.
141. Reichard, J.F., Motz, G.T., Puga, A., Heme oxygenase-1 induction by NRF2 requires inactivation of the transcriptional repressor BACH1. Nucleic Acids Res. 35 (2007), 7074–7086.
142. Lu, Z., Nie, G., Li, Y., Soe-Lin, S., Tao, Y., Cao, Y., Zhang, Z., Liu, N., Ponka, P., Zhao, B., Overexpression of mitochondrial ferritin sensitizes cells to oxidative stress via an iron-mediated mechanism. Antioxid. Redox Signal. 11 (2009), 1791–1803.
143. Liu, Q., Simpson, D.C., Gronert, S., Carbonylation of mitochondrial aconitase with 4-hydroxy-2-(E)-nonenal: localization and relative reactivity of addition sites. Biochim. Biophys. Acta 1834 (2013), 1144–1154.
144. Singh, S.P., Niemczyk, M., Saini, D., Awasthi, Y.C., Zimniak, L., Zimniak, P., Role of the electrophilic lipid peroxidation product 4-hydroxynonenal in the development and maintenance of obesity in mice. Biochemistry 47 (2008), 3900–3911.
145. Yarian, C.S., Rebrin, I., Sohal, R.S., Aconitase and ATP synthase are targets of malondialdehyde modification and undergo an age-related decrease in activity in mouse heart mitochondria. Biochem. Biophys. Res. Commun. 330 (2005), 151–156.
146. Paradies, G., Petrosillo, G., Paradies, V., Reiter, R.J., Ruggiero, F.M., Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease. J. Pineal Research 48 (2010), 297–310.
147. Paradies, G., Petrosillo, G., Pistolese, M., Di Venosa, N., Serena, D., Ruggiero, F.M., Lipid peroxidation and alterations to oxidative metabolism in mitochondria isolated from rat heart subjected to ischemia and reperfusion. Free Radical Biol. Med. 27 (1999), 42–50.
148. Sen, T., Sen, N., Tripathi, G., Chatterjee, U., Chakrabarti, S., Lipid peroxidation associated cardiolipin loss and membrane depolarization in rat brain mitochondria. Neurochem. Int. 49 (2006), 20–27.
149. Catala, A., Lipid peroxidation of membrane phospholipids generates hydroxy-alkenals and oxidized phospholipids active in physiological and/or pathological conditions. Chem. Phys. Lipids 157 (2009), 1–11.
150. Pizzimenti, S., Ciamporcero, E., Daga, M., Pettazzoni, P., Arcaro, A., Cetrangolo, G., Minelli, R., Dianzani, C., Lepore, A., Gentile, F., Barrera, G., Interaction of aldehydes derived from lipid peroxidation and membrane proteins. Front. Physiol., 4, 2013.
151. Chen, J.J., Yu, B.P., Alterations in mitochondrial membrane fluidity by lipid peroxidation products. Free Radical Biol. Med. 17 (1994), 411–418.
152. Rosales-Corral, S.A., Lopez-Armas, G., Cruz-Ramos, J., Melnikov, V.G., Tan, D.-X., Manchester, L.C., Munoz, R., Reiter, R.J., Alterations in lipid levels of mitochondrial membranes induced by amyloid-β A protective role of melatonin. Int. J. Alzheimer's Dis., 14(2012), 2012.
153. Betaneli, V., Petrov, E.P., Schwille, P., The role of lipids in VDAC oligomerization. Biophys. J. 102 (2012), 523–531.
154. Hedger, G., Rouse, S.L., Domański, J., Chavent, M., Koldsø H., Sansom, M.S.P., Lipid-loving ANTs: molecular simulations of cardiolipin interactions and the organization of the adenine nucleotide translocase in model mitochondrial membranes. Biochemistry 55 (2016), 6238–6249.
155. Montero, J., Mari, M., Colell, A., Morales, A., Basanez, G., Garcia-Ruiz, C., Fernandez-Checa, J.C., Cholesterol and peroxidized cardiolipin in mitochondrial membrane properties, permeabilization and cell death. Biochim. Biophys. Acta 1797 (2010), 1217–1224.
156. Musatov, A., Contribution of peroxidized cardiolipin to inactivation of bovine heart cytochrome c oxidase. Free Radical Biol. Med. 41 (2006), 238–246.
157. Raemy, E., Martinou, J.C., Involvement of cardiolipin in tBID-induced activation of BAX during apoptosis. Chem. Phys. Lipids 179 (2014), 70–74.
158. Shamas-Din, A., Bindner, S., Chi, X., Leber, B., Andrews, D.W., Fradin, C., Distinct lipid effects on tBid and Bim activation of membrane permeabilization by pro-apoptotic Bax. Biochem. J. 467 (2015), 495–505.
159. Galam, L., Failla, A., Soundararajan, R., Lockey, R.F., Kolliputi, N., 4-Hydroxynonenal regulates mitochondrial function in human small airway epithelial cells. Oncotarget 6 (2015), 41508–41521.
160. Zhong, H., Yin, H., Role of lipid peroxidation derived 4-hydroxynonenal (4-HNE) in cancer: focusing on mitochondria. Redox Biol. 4 (2015), 193–199.
161. Fukai, T., Ushio-Fukai, M., Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid. Redox Signal. 15 (2011), 1583–1606.
162. Kim, S.Y., Kim, T.-B., Moon, K.-a., Kim, T.J., Shin, D., Cho, Y.S., Moon, H.-B., Lee, K.-Y., Regulation of pro-inflammatory responses by lipoxygenases via intracellular reactive oxygen species in vitro and in vivo. Exp. Mol. Med. 40 (2008), 461–476.
163. Lee, S., Tak, E., Lee, J., Rashid, M.A., Murphy, M.P., Ha, J., Kim, S.S., Mitochondrial H2O2 generated from electron transport chain complex I stimulates muscle differentiation. Cell Res. 21 (2011), 817–834.
164. Schaur, R.J., Siems, W., Bresgen, N., Eckl, P.M., 4-Hydroxy-nonenal—A bioactive lipid peroxidation product. Biomolecules 5 (2015), 2247–2337.
165. Chuang, D.Y., Simonyi, A., Kotzbauer, P.T., Gu, Z., Sun, G.Y., Cytosolic phospholipase A2 plays a crucial role in ROS/NO signaling during microglial activation through the lipoxygenase pathway. J. Neuroinflammation, 12, 2015, 199.
166. Shibata, N., Kato, Y., Inose, Y., Hiroi, A., Yamamoto, T., Morikawa, S., Sawada, M., Kobayashi, M., 4-Hydroxy-2-nonenal upregulates and phosphorylates cytosolic phospholipase A(2) in cultured Ra2 microglial cells via MAPK pathways. Neuropathology 31 (2011), 122–128.
167. Zhu, D., Hu, C., Sheng, W., Tan, K.S., Haidekker, M.A., Sun, A.Y., Sun, G.Y., Lee, J.C., NAD(P)H oxidase-mediated reactive oxygen species production alters astrocyte membrane molecular order via phospholipase A2. Biochem. J. 421 (2009), 201–210.
168. Sun, G.Y., Chuang, D.Y., Zong, Y., Jiang, J., Lee, J.C.M., Gu, Z., Simonyi, A., Role of cytosolic phospholipase A(2) in oxidative and inflammatory signaling pathways in different cell types in the central nervous system. Mol. Neurobiol. 50 (2014), 6–14.
169. Conrad, M., Sandin, A., Forster, H., Seiler, A., Frijhoff, J., Dagnell, M., Bornkamm, G.W., Radmark, O., Hooft van Huijsduijnen, R., Aspenstrom, P., Bohmer, F., Ostman, A., 12/15-lipoxygenase-derived lipid peroxides control receptor tyrosine kinase signaling through oxidation of protein tyrosine phosphatases. Proc. Nat. Acad. Sci. U. S. A. 107 (2010), 15774–15779.
170. Hermann, P.M., Watson, S.N., Wildering, W.C., Phospholipase A2 – nexus of aging, oxidative stress, neuronal excitability, and functional decline of the aging nervous system? insights from a snail model system of neuronal aging and age-associated memory impairment. Front. Genet., 5, 2014.
171. Chen, M., Yang, Z.D., Smith, K.M., Carter, J.D., Nadler, J.L., Activation of 12-lipoxygenase in proinflammatory cytokine-mediated beta cell toxicity. Diabetologia 48 (2005), 486–495.
172. Slomiany, B.L., Slomiany, A., Involvement of constitutive nitric oxide synthase in ghrelin-induced cytosolic phospholipase A(2) activation in gastric mucosal cell protection against ethanol cytotoxicity. Inflammopharmacology 17 (2009), 245–253.
173. Doll, S., Conrad, M., Iron and ferroptosis: A still ill-defined liaison. IUBMB Life 69 (2017), 423–434.
174. Guaraldo, M., Santambrogio, P., Rovelli, E., Di Savino, A., Saglio, G., Cittaro, D., Roetto, A., Levi, S., Characterization of human mitochondrial ferritin promoter: identification of transcription factors and evidences of epigenetic control. Sci. Rep., 6, 2016, 33432.
175. Yang, H., Yang, M., Guan, H., Liu, Z., Zhao, S., Takeuchi, S., Yanagisawa, D., Tooyama, I., Mitochondrial ferritin in neurodegenerative diseases. Neurosci. Res. 77 (2013), 1–7.
176. Chaum, E., Yin, J., Yang, H., Thomas, F., Lang, J.C., Quantitative AP-1 gene regulation by oxidative stress in the human retinal pigment epithelium. J. Cell. Biochem. 108 (2009), 1280–1291.
177. Invernizzi, R., Travaglino, E., Della Porta, M.G., Gallì A., Malcovati, L., Rosti, V., Bergamaschi, G., Erba, B.G., Bellistri, F., Bastia, R., Santambrogio, P., Levi, S., Cazzola, M., Effects of mitochondrial ferritin overexpression in normal and sideroblastic erythroid progenitors. Br. J. Haematol. 161 (2013), 726–737.
178. Santambrogio, P., Erba, B.G., Campanella, A., Cozzi, A., Causarano, V., Cremonesi, L., Gallì A., Della Porta, M.G., Invernizzi, R., Levi, S., Over-expression of mitochondrial ferritin affects the JAK2/STAT5 pathway in K562 cells and causes mitochondrial iron accumulation. Haematologica 96 (2011), 1424–1432.
179. Bresgen, N., Jaksch, H., Lacher, H., Ohlenschlager, I., Uchida, K., Eckl, P.M., Iron-mediated oxidative stress plays an essential role in ferritin-induced cell death. Free Radical Biol. Med. 48 (2010), 1347–1357.
180. Antunes, F., Cadenas, E., Brunk, U.T., Apoptosis induced by exposure to a low steady-state concentration of H2O2 is a consequence of lysosomal rupture. Biochem. J. 356 (2001), 549–555.
181. Kurz, T., Eaton, J.W., Brunk, U.T., The role of lysosomes in iron metabolism and recycling. Int. J. Biochem. Cell Biol. 43 (2011), 1686–1697.
182. Yu, Z., Persson, H.L., Eaton, J.W., Brunk, U.T., Intralysosomal iron: a major determinant of oxidant-induced cell death. Free Radical Biol. Med. 34 (2003), 1243–1252.
183. Zdolsek, J.M., Svensson, I., Effect of reactive oxygen species on lysosomal membrane integrity. A study on a lysosomal fraction. Virchows Archiv. B 64 (1993), 401–406.
184. Hyun, D.H., Lee, M.H., Halliwell, B., Jenner, P., Proteasomal dysfunction induced by 4-hydroxy-2,3-trans-nonenal, an end-product of lipid peroxidation: a mechanism contributing to neurodegeneration?. J. Neurochem. 83 (2002), 360–370.
185. Krohne, T.U., Kaemmerer, E., Holz, F.G., Kopitz, J., Lipid peroxidation products reduce lysosomal protease activities in human retinal pigment epithelial cells via two different mechanisms of action. Exp. Eye Res. 90 (2010), 261–266.
186. Okada, K., Wangpoengtrakul, C., Osawa, T., Toyokuni, S., Tanaka, K., Uchida, K., 4-Hydroxy-2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress. Identification of proteasomes as target molecules. J. Biol. Chem. 274 (1999), 23787–23793.
187. Casañas-Sanchez, V., Pérez, J., Fabelo, N., Quinto-Alemany, D., Diaz, M., Docosahexaenoic (DHA) modulates phospholipid-hydroperoxide glutathione peroxidase (Gpx4) gene expression to ensure self-protection from oxidative damage in hippocampal cells. Front. Physiol., 6, 2015.
188. Fruhwirth, G.O., Hermetter, A., Mediation of apoptosis by oxidized phospholipids. Sub-Cell. Biochem. 49 (2008), 351–367.
189. Volinsky, R., Kinnunen, P.K., Oxidized phosphatidylcholines in membrane-level cellular signaling: from biophysics to physiology and molecular pathology. FEBS J. 280 (2013), 2806–2816.
190. Singh, M., Dang, T.N., Arseneault, M., Ramassamy, C., Role of by-products of lipid oxidation in Alzheimer's disease brain: a focus on acrolein. J. Alzheimers Dis. 21 (2010), 741–756.
191. Ishikado, A., Morino, K., Nishio, Y., Nakagawa, F., Mukose, A., Sono, Y., Yoshioka, N., Kondo, K., Sekine, O., Yoshizaki, T., Ugi, S., Uzu, T., Kawai, H., Makino, T., Okamura, T., Yamamoto, M., Kashiwagi, A., Maegawa, H., 4-Hydroxy hexenal derived from docosahexaenoic acid protects endothelial cells via Nrf2 activation. PloS One, 8, 2013, e69415.
192. Kusunoki, C., Yang, L., Yoshizaki, T., Nakagawa, F., Ishikado, A., Kondo, M., Morino, K., Sekine, O., Ugi, S., Nishio, Y., Kashiwagi, A., Maegawa, H., Omega-3 polyunsaturated fatty acid has an anti-oxidant effect via the Nrf-2/HO-1 pathway in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 430 (2013), 225–230.
193. Yang, Y.C., Lii, C.K., Wei, Y.L., Li, C.C., Lu, C.Y., Liu, K.L., Chen, H.W., Docosahexaenoic acid inhibition of inflammation is partially via cross-talk between Nrf2/heme oxygenase 1 and IKK/NF-kappaB pathways. J. Nutrit. Biochem. 24 (2013), 204–212.
194. Nguyen, T., Nioi, P., Pickett, C.B., The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J. Biol. Chem. 284 (2009), 13291–13295.
195. Wu, K.C., Cui, J.Y., Klaassen, C.D., Beneficial role of Nrf2 in regulating NADPH generation and consumption. Toxicol. Sci. 123 (2011), 590–600.
196. Habib, E., Linher-Melville, K., Lin, H.-X., Singh, G., Expression of xCT and activity of system x(c)(−) are regulated by NRF2 in human breast cancer cells in response to oxidative stress. Redox Biol. 5 (2015), 33–42.
197. Qiang, W., Cahill, J.M., Liu, J., Kuang, X., Liu, N., Scofield, V.L., Voorhees, J.R., Reid, A.J., Yan, M., Lynn, W.S., Wong, P.K., Activation of transcription factor Nrf-2 and its downstream targets in response to moloney murine leukemia virus ts1-induced thiol depletion and oxidative stress in astrocytes. J. Virol. 78 (2004), 11926–11938.
198. Griffith, O.W., Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radical Biol. Med. 27 (1999), 922–935.
199. Franco, R., Schoneveld, O.J., Pappa, A., Panayiotidis, M.I., The central role of glutathione in the pathophysiology of human diseases. Arch. Physiol. Biochem. 113 (2007), 234–258.
200. Awasthi, Y.C., Sharma, R., Sharma, A., Yadav, S., Singhal, S.S., Chaudhary, P., Awasthi, S., Self-regulatory role of 4-hydroxynonenal in signaling for stress-induced programmed cell death. Free Radical Biol. Med., 45, 2008.
201. Singhal, S.S., Singh, S.P., Singhal, P., Horne, D., Singhal, J., Awasthi, S., Antioxidant role of glutathione S-transferases: 4-Hydroxynonenal, a key molecule in stress-mediated signaling. Toxicol. Appl. Pharmacol. 289 (2015), 361–370.
202. Balogh, L.M., Atkins, W.M., Interactions of glutathione transferases with 4-hydroxynonenal. Drug Metab. Rev. 43 (2011), 165–178.
203. Homolya, L., Varadi, A., Sarkadi, B., Multidrug resistance-associated proteins: export pumps for conjugates with glutathione, glucuronate or sulfate. BioFactors (Oxford, England) 17 (2003), 103–114.
204. Morris, G., Anderson, G., Dean, O., Berk, M., Galecki, P., Martin-Subero, M., The glutathione system: a new drug target in neuroimmune disorders. Mol. Neurobiol. 50 (2014), 1059–1084.
205. Bridges, R.J., Natale, N.R., Patel, S.A., System x(c)(-) cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS. Br. J. Pharmacol. 165 (2012), 20–34.
206. Lewerenz, J., Hewett, S.J., Huang, Y., Lambros, M., Gout, P.W., Kalivas, P.W., Massie, A., Smolders, I., Methner, A., Pergande, M., Smith, S.B., Ganapathy, V., Maher, P., The cystine/glutamate antiporter system x(c)(−) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid. Redox Signal. 18 (2013), 522–555.
207. Pampliega, O., Domercq, M., Soria, F.N., Villoslada, P., Rodríguez-Antigüedad, A., Matute, C., Increased expression of cystine/glutamate antiporter in multiple sclerosis. J. Neuroinflammation, 8, 2011, 63.
208. Anderson, E.J., Katunga, L.A., Willis, M.S., Mitochondria as a source and target of lipid peroxidation products in healthy and diseased heart. Clin. Exp. Pharmacol. Physiol., 39, 2012, 10.1111/j.1440-1681.2011.05641.x.
209. Imai, H., Nakagawa, Y., Biological significance of phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) in mammalian cells. Free radical biology & medicine 34 (2003), 145–169.
210. Brigelius-Flohe, R., Maiorino, M., Glutathione peroxidases. Biochimica et biophysica acta 1830 (2013), 3289–3303.
211. Yu, Y., Song, J., Guo, X., Wang, S., Yang, X., Chen, L., Wei, J., Characterization and structural analysis of human selenium-dependent glutathione peroxidase 4 mutant expressed in Escherichia coli. Free Radical Biol. Med. 71 (2014), 332–338.
212. Arrigo, A.P., Virot, S., Chaufour, S., Firdaus, W., Kretz-Remy, C., Diaz-Latoud, C., Hsp27 consolidates intracellular redox homeostasis by upholding glutathione in its reduced form and by decreasing iron intracellular levels. Antioxid. Redox Signal. 7 (2005), 414–422.
213. Chen, H., Zheng, C., Zhang, Y., Chang, Y.Z., Qian, Z.M., Shen, X., Heat shock protein 27 downregulates the transferrin receptor 1-mediated iron uptake. Int. J. Biochem. Cell Biol. 38 (2006), 1402–1416.
214. Mehlen, P., Hickey, E., Weber, L.A., Arrigo, A.P., Large unphosphorylated aggregates as the active form of hsp27 which controls intracellular reactive oxygen species and glutathione levels and generates a protection against TNFalpha in NIH-3T3-ras cells. Biochem. Biophys. Res. Commun. 241 (1997), 187–192.
215. Ullrich, O., Grune, T., Henke, W., Esterbauer, H., Siems, W.G., Identification of metabolic pathways of the lipid peroxidation product 4-hydroxynonenal by mitochondria isolated from rat kidney cortex. FEBS Lett. 352 (1994), 84–86.
216. Imai, H., Hirao, F., Sakamoto, T., Sekine, K., Mizukura, Y., Saito, M., Kitamoto, T., Hayasaka, M., Hanaoka, K., Nakagawa, Y., Early embryonic lethality caused by targeted disruption of the mouse PHGPx gene. Biochem. Biophys. Res. Commun. 305 (2003), 278–286.
217. Savaskan, N.E., Ufer, C., Kuhn, H., Borchert, A., Molecular biology of glutathione peroxidase 4: from genomic structure to developmental expression and neural function. Biol. Chem. 388 (2007), 1007–1017.
218. Brigelius-Flohe, R., Tissue-specific functions of individual glutathione peroxidases. Free Radical Biol. Med. 27 (1999), 951–965.
219. Brigelius-Flohe, R., Aumann, K.D., Blocker, H., Gross, G., Kiess, M., Kloppel, K.D., Maiorino, M., Roveri, A., Schuckelt, R., Usani, F., et al. Phospholipid-hydroperoxide glutathione peroxidase. Genomic DNA, cDNA, and deduced amino acid sequence. J. B. Chem. 269 (1994), 7342–7348.
220. Antunes, F., Salvador, A., Pinto, R.E., PHGPx and phospholipase A2/GPx: comparative importance on the reduction of hydroperoxides in rat liver mitochondria. Free Radical Biol. Med. 19 (1995), 669–677.
221. Scheerer, P., Borchert, A., Krauss, N., Wessner, H., Gerth, C., Hohne, W., Kuhn, H., Structural basis for catalytic activity and enzyme polymerization of phospholipid hydroperoxide glutathione peroxidase-4 (GPx4). Biochemistry 46 (2007), 9041–9049.
222. Imai, H., Sumi, D., Sakamoto, H., Hanamoto, A., Arai, M., Chiba, N., Nakagawa, Y., Overexpression of phospholipid hydroperoxide glutathione peroxidase suppressed cell death due to oxidative damage in rat basophile leukemia cells (RBL-2H3). Biochem. Biophys. Res. Commun. 222 (1996), 432–438.
223. Yagi, K., Komura, S., Kojima, H., Sun, Q., Nagata, N., Ohishi, N., Nishikimi, M., Expression of human phospholipid hydroperoxide glutathione peroxidase gene for protection of host cells from lipid hydroperoxide-mediated injury. Biochem. Biophys. Res. Commun. 219 (1996), 486–491.
224. Brigelius-Flohe, R., Maurer, S., Lotzer, K., Bol, G., Kallionpaa, H., Lehtolainen, P., Viita, H., Yla-Herttuala, S., Overexpression of PHGPx inhibits hydroperoxide-induced oxidation, NFkappaB activation and apoptosis and affects oxLDL-mediated proliferation of rabbit aortic smooth muscle cells. Atherosclerosis 152 (2000), 307–316.
225. Arai, M., Imai, H., Koumura, T., Yoshida, M., Emoto, K., Umeda, M., Chiba, N., Nakagawa, Y., Mitochondrial phospholipid hydroperoxide glutathione peroxidase plays a major role in preventing oxidative injury to cells. J. Biol. Chem. 274 (1999), 4924–4933.
226. Liang, H., Van Remmen, H., Frohlich, V., Lechleiter, J., Richardson, A., Ran, Q., Gpx4 protects mitochondrial ATP generation against oxidative damage. Biochem. Biophys. Res. Commun. 356 (2007), 893–898.
227. Ran, Q., Gu, M., Van Remmen, H., Strong, R., Roberts, J.L., Richardson, A., Glutathione peroxidase 4 protects cortical neurons from oxidative injury and amyloid toxicity. J. Neurosci. Res. 84 (2006), 202–208.
228. Chen, L., Hambright, W.S., Na, R., Ran, Q., Ablation of the ferroptosis inhibitor glutathione peroxidase 4 in neurons results in rapid motor neuron degeneration and paralysis. J. Biol. Chem. 290 (2015), 28097–28106.
229. Hambright, W.S., Fonseca, R.S., Chen, L., Na, R., Ran, Q., Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration. Redox Biol. 12 (2017), 8–17.
230. Kaspar, J.W., Jaiswal, A.K., An autoregulatory loop between Nrf2 and Cul3-Rbx1 controls their cellular abundance. J. Biol. Chem. 285 (2010), 21349–21358.
231. Ariga, H., Takahashi-Niki, K., Kato, I., Maita, H., Niki, T., Iguchi-Ariga, S.M., Neuroprotective function of DJ-1 in Parkinson's disease. Oxidative Med. Cell. Longevity(2013), 2013, 683920.
232. Milani, P., Ambrosi, G., Gammoh, O., Blandini, F., Cereda, C., SOD1 and DJ-1 converge at Nrf2 pathway: a clue for antioxidant therapeutic potential in neurodegeneration. Oxidative Med. Cell. Longevity(2013), 2013, 836760.
233. Lev, N., Ickowicz, D., Melamed, E., Offen, D., Oxidative insults induce DJ-1 upregulation and redistribution: implications for neuroprotection. Neurotoxicology 29 (2008), 397–405.
234. Shadrach, K.G., Rayborn, M.E., Hollyfield, J.G., Bonilha, V.L., DJ-1-dependent regulation of oxidative stress in the retinal pigment epithelium (RPE). PloS One, 8, 2013, e67983.
235. Clements, C.M., McNally, R.S., Conti, B.J., Mak, T.W., Ting, J.P.-Y., DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc. Nat. Acad. Sci. 103 (2006), 15091–15096.
236. Liu, C., Chen, Y., Kochevar, I.E., Jurkunas, U.V., Decreased DJ-1 leads to impaired Nrf2-regulated antioxidant defense and increased UV–A- induced apoptosis in corneal endothelial Cells. Invest. Ophthalmol. Vis. Sci. 55 (2014), 5551–5560.
237. Saidu, N.E., Noe, G., Cerles, O., Cabel, L., Kavian-Tessler, N., Chouzenoux, S., Bahuaud, M., Chereau, C., Nicco, C., Leroy, K., Borghese, B., Goldwasser, F., Batteux, F., Alexandre, J., Dimethyl fumarate controls the NRF2/DJ-1 axis in cancer cells: therapeutic applications. Mol. Cancer Ther. 16 (2017), 529–539.
238. Ishikawa, S., Taira, T., Takahashi-Niki, K., Niki, T., Ariga, H., Iguchi-Ariga, S.M.M., Human DJ-1-specific transcriptional activation of tyrosine hydroxylase Gene. J. Biol. Chem. 285 (2010), 39718–39731.
239. Wilson, M.A., The role of cysteine oxidation in DJ-1 function and dysfunction. Antioxid. Redox Signal. 15 (2011), 111–122.
240. Cao, J., Ying, M., Xie, N., Lin, G., Dong, R., Zhang, J., Yan, H., Yang, X., He, Q., Yang, B., The oxidation states of DJ-1 dictate the cell fate in response to oxidative stress triggered by 4-hpr: autophagy or apoptosis?. Antioxid. Redox Signal. 21 (2014), 1443–1459.
241. Ito, G., Ariga, H., Nakagawa, Y., Iwatsubo, T., Roles of distinct cysteine residues in S-nitrosylation and dimerization of DJ-1. Biochem. Biophys. Res. Commun. 339 (2006), 667–672.
242. Alary, J., Bravais, F., Cravedi, J.P., Debrauwer, L., Rao, D., Bories, G., Mercapturic acid conjugates as urinary end metabolites of the lipid peroxidation product 4-hydroxy-2-nonenal in the rat. Chem. Res. Toxicol. 8 (1995), 34–39.
243. Alary, J., Fernandez, Y., Debrauwer, L., Perdu, E., Gueraud, F., Identification of intermediate pathways of 4-hydroxynonenal metabolism in the rat. Chem. Res. Toxicol. 16 (2003), 320–327.
244. Alary, J., Gueraud, F., Cravedi, J.P., Fate of 4-hydroxynonenal in vivo: disposition and metabolic pathways. Mol. Aspects Med. 24 (2003), 177–187.
245. Keller, J., Baradat, M., Jouanin, I., Debrauwer, L., Guéraud, F., “Twin peaks”: searching for 4-hydroxynonenal urinary metabolites after oral administration in rats. Redox Biol. 4 (2015), 136–148.
246. Gil, L., Siems, W., Mazurek, B., Gross, J., Schroeder, P., Voss, P., Grune, T., Age-associated analysis of oxidative stress parameters in human plasma and erythrocytes. Free Radical Res. 40 (2006), 495–505.
247. Selley, M.L., Bartlett, M.R., McGuiness, J.A., Hapel, A.J., Ardlie, N.G., Determination of the lipid peroxidation product trans-4-hydroxy-2-nonenal in biological samples by high-performance liquid chromatography and combined capillary column gas chromatography-negative-ion chemical ionisation mass spectrometry. J. Chromatogr. 488 (1989), 329–340.
248. Mishra, A.K., Tiwari, A., Iron overload in Beta thalassaemia major and intermedia patients. Mædica 8 (2013), 328–332.
249. Novembrino, C., Porcella, A., Conte, D., de Vecchi, A.F., Buccianti, G., Lonati, S., Duca, L., Ciani, A., Bamonti-Catena, F., Erythrocyte ferritin concentration: analytical performance of the immunoenzymatic IMx-ferritin (Abbott) assay. Clin. Chem. Lab. Med. 43 (2005), 449–453.
250. Camaschella, C., Poggiali, E., Towards explaining “unexplained hyperferritinemia”. Haematologica 94 (2009), 307–309.
251. Jensen, J.H., Tang, H., Tosti, C.L., Swaminathan, S.V., Nunez, A., Hultman, K., Szulc, K.U., Wu, E.X., Kim, D., Sheth, S., Brown, T.R., Brittenham, G.M., Separate MRI quantification of dispersed (ferritin-like) and aggregated (hemosiderin-like) storage iron. Magn. Reson. Med. 63 (2010), 1201–1209.
252. Wu, E.X., Kim, D., Tosti, C.L., Tang, H., Jensen, J.H., Cheung, J.S., Feng, L., Au, W.Y., Ha, S.Y., Sheth, S.S., Brown, T.R., Brittenham, G.M., Magnetic resonance assessment of iron overload by separate measurement of tissue ferritin and hemosiderin iron. Annal. N. Y. Acad. Sci. 1202 (2010), 115–122.
253. Kruer, M.C., Boddaert, N., Schneider, S.A., Houlden, H., Bhatia, K.P., Gregory, A., Anderson, J.C., Rooney, W.D., Hogarth, P., Hayflick, S.J., Neuroimaging features of neurodegeneration with brain iron accumulation. AJNR. Am. J. Neuroradiol. 33 (2012), 407–414.
254. Acosta-Cabronero, J., Williams, G.B., Cardenas-Blanco, A., Arnold, R.J., Lupson, V., Nestor, P.J., In vivo quantitative susceptibility mapping (QSM) in Alzheimer's disease. PloS One, 8, 2013, e81093.
255. Qin, Y., Zhu, W., Zhan, C., Zhao, L., Wang, J., Tian, Q., Wang, W., Investigation on positive correlation of increased brain iron deposition with cognitive impairment in Alzheimer disease by using quantitative MR R2’ mapping. J. Huazhong Univ. Sci. Technol. Med. Sci. 31 (2011), 578–585.
256. Zhu, W.Z., Zhong, W.D., Wang, W., Zhan, C.J., Wang, C.Y., Qi, J.P., Wang, J.Z., Lei, T., Quantitative MR phase-corrected imaging to investigate increased brain iron deposition of patients with Alzheimer disease. Radiology 253 (2009), 497–504.
257. Derry, P.J., Kent, T.A., Correlating quantitative susceptibility mapping with cognitive decline in Alzheimer's disease. Brain 140 (2017), 2069–2072.
258. Lavados, M., Guillon, M., Mujica, M.C., Rojo, L.E., Fuentes, P., Maccioni, R.B., Mild cognitive impairment and Alzheimer patients display different levels of redox-active CSF iron. J. Alzheimers Dis. 13 (2008), 225–232.
259. Tao, Y., Wang, Y., Rogers, J.T., Wang, F., Perturbed iron distribution in Alzheimer's disease serum, cerebrospinal fluid, and selected brain regions: a systematic review and meta-analysis. J. Alzheimers. Dis. 42 (2014), 679–690.
260. Smith, M.A., Zhu, X., Tabaton, M., Liu, G., McKeel, D.W. Jr., Cohen, M.L., Wang, X., Siedlak, S.L., Dwyer, B.E., Hayashi, T., Nakamura, M., Nunomura, A., Perry, G., Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J. Alzheimers. Dis. 19 (2010), 363–372.
261. Ayton, S., Fazlollahi, A., Bourgeat, P., Raniga, P., Ng, A., Lim, Y.Y., Diouf, I., Farquharson, S., Fripp, J., Ames, D., Doecke, J., Desmond, P., Ordidge, R., Masters, C.L., Rowe, C.C., Maruff, P., Villemagne, V.L., Salvado, O., Bush, A.I., Cerebral quantitative susceptibility mapping predicts amyloid-β-related cognitive decline. Brain 140 (2017), 2112–2119.
262. Kim, H.G., Park, S., Rhee, H.Y., Lee, K.M., Ryu, C.W., Rhee, S.J., Lee, S.Y., Wang, Y., Jahng, G.H., Quantitative susceptibility mapping to evaluate the early stage of Alzheimer's disease. NeuroImage. Clin. 16 (2017), 429–438.
263. Morris, C.M., Candy, J.M., Kerwin, J.M., Edwardson, J.A., Transferrin receptors in the normal human hippocampus and in Alzheimer's disease. Neuropathol. Appl. Neurobiol. 20 (1994), 473–477.
264. Raha, A.A., Vaishnav, R.A., Friedland, R.P., Bomford, A., Raha-Chowdhury, R., The systemic iron-regulatory proteins hepcidin and ferroportin are reduced in the brain in Alzheimer's disease. Acta Neuropathol. Commun., 1, 2013, 55.
265. Jellinger, K., Paulus, W., Grundke-Iqbal, I., Riederer, P., Youdim, M.B., Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J. Neural. Transm. Park. Dis. Dement. Sect. 2 (1990), 327–340.
266. Kristinsson, J., Snaedal, J., Torsdottir, G., Johannesson, T., Ceruloplasmin and iron in Alzheimer's disease and Parkinson's disease: a synopsis of recent studies. Neuropsychiatr. Dis. Treat. 8 (2012), 515–521.
267. Li, D.D., Zhang, W., Wang, Z.Y., Zhao, P., Serum copper, zinc, and iron levels in patients with Alzheimer's disease: a meta-analysis of case-control studies. Front. Aging Neurosci., 9, 2017, 300.
268. Sternberg, Z., Hu, Z., Sternberg, D., Waseh, S., Quinn, J.F., Wild, K., Jeffrey, K., Zhao, L., Garrick, M., Serum hepcidin levels, iron dyshomeostasis and cognitive loss in Alzheimer's disease. Aging Dis. 8 (2017), 215–227.
269. Hare, D.J., Doecke, J.D., Faux, N.G., Rembach, A., Volitakis, I., Fowler, C.J., Grimm, R., Doble, P.A., Cherny, R.A., Masters, C.L., Bush, A.I., Roberts, B.R., Decreased plasma iron in Alzheimer's disease is due to transferrin desaturation. ACS Chem. Neurosci. 6 (2015), 398–402.
270. Squitti, R., Salustri, C., Siotto, M., Ventriglia, M., Vernieri, F., Lupoi, D., Cassetta, E., Rossini, P.M., Ceruloplasmin/transferrin ratio changes in Alzheimer's disease. Int. J. Alzheimer's Dis., 2011, 2011, 6.
271. Snowden, S.G., Ebshiana, A.A., Hye, A., An, Y., Pletnikova, O., O'Brien, R., Troncoso, J., Legido-Quigley, C., Thambisetty, M., Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: A nontargeted metabolomic study. PLoS Med., 14, 2017, e1002266.
272. Thomas, M.H., Pelleieux, S., Vitale, N., Olivier, J.L., Dietary arachidonic acid as a risk factor for age-associated neurodegenerative diseases: potential mechanisms. Biochimie 130 (2016), 168–177.
273. Stephenson, D.T., Lemere, C.A., Selkoe, D.J., Clemens, J.A., Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer's disease brain. Neurobiol. Dis. 3 (1996), 51–63.
274. Kuwata, H., Hara, S., Inhibition of long-chain acyl-CoA synthetase 4 facilitates production of 5, 11-dihydroxyeicosatetraenoic acid via the cyclooxygenase-2 pathway. Biochem. Biophys. Res. Commun. 465 (2015), 528–533.
275. Sanchez-Mejia, R.O., Mucke, L., Phospholipase A(2) and arachidonic acid in Alzheimer's disease. Biochim. Biophys. Acta 1801 (2010), 784–790.
276. Bradley-Whitman, M.A., Lovell, M.A., Biomarkers of lipid peroxidation in Alzheimer disease (AD): an update. Arch. Toxicol. 89 (2015), 1035–1044.
277. Butterfield, D.A., Bader Lange, M.L., Sultana, R., Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. Biochim. Biophys. Acta 1801 (2010), 924–929.
278. Sultana, R., Perluigi, M., Allan Butterfield, D., Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain. Free Radical Biol. Med. 62 (2013), 157–169.
279. Sultana, R., Piroddi, M., Galli, F., Butterfield, D.A., Protein levels and activity of some antioxidant enzymes in hippocampus of subjects with amnestic mild cognitive impairment. Neurochem. Res. 33 (2008), 2540–2546.
280. Montine, T.J., Neely, M.D., Quinn, J.F., Beal, M.F., Markesbery, W.R., Roberts, L.J., Morrow, J.D., Lipid peroxidation in aging brain and alzheimer's disease. Free Radical Biol. Med. 33 (2002), 620–626.
281. Padurariu, M., Ciobica, A., Hritcu, L., Stoica, B., Bild, W., Stefanescu, C., Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease. Neurosci. Lett. 469 (2010), 6–10.
282. Di Francesco, A., Arosio, B., Gussago, C., Dainese, E., Mari, D., D'Addario, C., Maccarrone, M., Involvement of 5-lipoxygenase in Alzheimer's disease: a role for DNA methylation. J. Alzheimers. Dis. 37 (2013), 3–8.
283. Ikonomovic, M.D., Abrahamson, E.E., Uz, T., Manev, H., Dekosky, S.T., Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease. J. Histochem. Cytochem. 56 (2008), 1065–1073.
284. Pratico, D., Zhukareva, V., Yao, Y., Uryu, K., Funk, C.D., Lawson, J.A., Trojanowski, J.Q., Lee, V.M., 12/15-lipoxygenase is increased in Alzheimer's disease: possible involvement in brain oxidative stress. Am. J. Pathol. 164 (2004), 1655–1662.
285. Yao, Y., Clark, C.M., Trojanowski, J.Q., Lee, V.M., Pratico, D., Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment. Annal. Neurol. 58 (2005), 623–626.
286. Czapski, G.A., Czubowicz, K., Strosznajder, J.B., Strosznajder, R.P., The lipoxygenases: their regulation and implication in Alzheimer's disease. Neurochem. Res. 41 (2016), 243–257.
287. Aksenov, M.Y., Markesbery, W.R., Changes in thiol content and expression of glutathione redox system genes in the hippocampus and cerebellum in Alzheimer's disease. Neurosci. Lett. 302 (2001), 141–145.
288. Mandal, P.K., Saharan, S., Tripathi, M., Murari, G., Brain glutathione levels–a novel biomarker for mild cognitive impairment and Alzheimer's disease. Biol. Psychiatry 78 (2015), 702–710.
289. Calabrese, V., Sultana, R., Scapagnini, G., Guagliano, E., Sapienza, M., Bella, R., Kanski, J., Pennisi, G., Mancuso, C., Stella, A.M., Butterfield, D.A., Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid. Redox Signal. 8 (2006), 1975–1986.
290. Lloret, A., Badia, M.C., Mora, N.J., Pallardo, F.V., Alonso, M.D., Vina, J., Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. J. Alzheimers Dis. 17 (2009), 143–149.
291. Baldeiras, I., Santana, I., Proenca, M.T., Garrucho, M.H., Pascoal, R., Rodrigues, A., Duro, D., Oliveira, C.R., Peripheral oxidative damage in mild cognitive impairment and mild Alzheimer's disease. J. Alzheimers Dis. 15 (2008), 117–128.
292. Baldeiras, I., Santana, I., Proenca, M.T., Garrucho, M.H., Pascoal, R., Rodrigues, A., Duro, D., Oliveira, C.R., Oxidative damage and progression to Alzheimer's disease in patients with mild cognitive impairment. J. Alzheimers Dis. 21 (2010), 1165–1177.
293. Barberger-Gateau, P., Samieri, C., Féart, C., Plourde, M., Dietary omega 3 polyunsaturated fatty acids and Alzheimer's disease: interaction with apolipoprotein E genotype. Curr. Alzheimer Res. 8 (2011), 479–491.
294. Krajcovicova-Kudlackova, M., Paukova, V., Bacekova, M., Dusinska, M., Lipid peroxidation in relation to vitamin C and vitamin E levels. Central Eur. J. Public Health 12 (2004), 46–48.
295. Imai, H., Matsuoka, M., Kumagai, T., Sakamoto, T., Koumura, T., Lipid peroxidation-dependent cell death regulated by GPx4 and ferroptosis. Curr. Topics Microbiol. Immunol. 403 (2017), 143–170.
296. Sunday, O., Adekunle, M., Temitope, O., Richard, A., Samuel, A., Olufunminyi, A., Elizabeth, O., Alteration in antioxidants level and lipid peroxidation of patients with neurodegenerative diseases {Alzheimer's disease and Parkinson disease}. Int. J. Nutr. Pharmacol. Neurol. Dis. 4 (2014), 146–152.
297. Yoo, M.-H., Gu, X., Xu, X.-M., Kim, J.-Y., Carlson, B.A., Patterson, A.D., Cai, H., Gladyshev, V.N., Hatfield, D.L., Delineating the role of glutathione peroxidase 4 in protecting cells against lipid hydroperoxide damage and in Alzheimer's disease. Antioxid. Redox Signal. 12 (2010), 819–827.
298. Sato, H., Nomura, S., Maebara, K., Sato, K., Tamba, M., Bannai, S., Transcriptional control of cystine/glutamate transporter gene by amino acid deprivation. Biochem. Biophys. Res. Commun. 325 (2004), 109–116.
299. Sato, H., Kuriyama-Matsumura, K., Hashimoto, T., Sasaki, H., Wang, H., Ishii, T., Mann, G.E., Bannai, S., Effect of oxygen on induction of the cystine transporter by bacterial lipopolysaccharide in mouse peritoneal macrophages. J. Biol. Chem. 276 (2001), 10407–10412.
300. Salminen, A., Kauppinen, A., Suuronen, T., Kaarniranta, K., Ojala, J., ER stress in Alzheimer's disease: a novel neuronal trigger for inflammation and Alzheimer's pathology. J. Neuroinflammation, 6, 2009, 41.
301. Barger, S.W., Basile, A.S., Activation of microglia by secreted amyloid precursor protein evokes release of glutamate by cystine exchange and attenuates synaptic function. J. Neurochem. 76 (2001), 846–854.
302. Schallier, A., Smolders, I., Van Dam, D., Loyens, E., De Deyn, P.P., Michotte, A., Michotte, Y., Massie, A., Region- and age-specific changes in glutamate transport in the AbetaPP23 mouse model for Alzheimer's disease. J. Alzheimers Dis. 24 (2011), 287–300.
303. Kerr, F., Sofola-Adesakin, O., Ivanov, D.K., Gatliff, J., Gomez Perez-Nievas, B., Bertrand, H.C., Martinez, P., Callard, R., Snoeren, I., Cochemé H.M., Adcott, J., Khericha, M., Castillo-Quan, J.I., Wells, G., Noble, W., Thornton, J., Partridge, L., Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer's disease. PLoS Genet., 13, 2017, e1006593.
304. Choi, J., Sullards, M.C., Olzmann, J.A., Rees, H.D., Weintraub, S.T., Bostwick, D.E., Gearing, M., Levey, A.I., Chin, L.-S., Li, L., Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J. Biol. Chem. 281 (2006), 10816–10824.
305. Renkawek, K., Bosman, G.J., de Jong, W.W., Expression of small heat-shock protein hsp 27 in reactive gliosis in Alzheimer disease and other types of dementia. Acta Neuropathol. 87 (1994), 511–519.
306. Zhang, X., Shi, J., Tian, J., Robinson, A.C., Davidson, Y.S., Mann, D.M., Expression of one important chaperone protein, heat shock protein 27, in neurodegenerative diseases. Alzheimers Res. Ther., 6, 2014, 78.
307. Toth, M.E., Szegedi, V., Varga, E., Juhasz, G., Horvath, J., Borbely, E., Csibrany, B., Alfoldi, R., Lenart, N., Penke, B., Santha, M., Overexpression of Hsp27 ameliorates symptoms of Alzheimer's disease in APP/PS1 mice. Cell Stress Chaperones 18 (2013), 759–771.
308. Shimohama, S., Tanino, H., Kawakami, N., Okamura, N., Kodama, H., Yamaguchi, T., Hayakawa, T., Nunomura, A., Chiba, S., Perry, G., Smith, M.A., Fujimoto, S., Activation of NADPH oxidase in Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 273 (2000), 5–9.
309. Wilkinson, B.L., Landreth, G.E., The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease. J. Neuroinflammation 3 (2006), 1–12.
310. Dingjan, I., Verboogen, D.R.J., Paardekooper, L.M., Revelo, N.H., Sittig, S.P., Visser, L.J., Mollard, G.Fv, Henriet, S.S.V., Figdor, C.G., ter Beest, M., van den Bogaart, G., Lipid peroxidation causes endosomal antigen release for cross-presentation. Sci. Rep., 6, 2016, 22064.
311. Huang, J., Brumell, J.H., NADPH oxidases contribute to autophagy regulation. Autophagy 5 (2009), 887–889.
312. Funderburk, S.F., Marcellino, B.K., Yue, Z., Cell “Self-Eating” (autophagy) mechanism in Alzheimer's disease. Mount Sinai J. Med. 77 (2010), 59–68.
313. Li, Q., Liu, Y., Sun, M., Autophagy and Alzheimer's disease. Cell Mol. Neurobiol. 37 (2017), 377–388.
314. Toh, W.H., Gleeson, P.A., Dysregulation of intracellular trafficking and endosomal sorting in Alzheimer's disease: controversies and unanswered questions. Biochem. J. 473 (2016), 1977–1993.
315. Gowrishankar, S., Yuan, P., Wu, Y., Schrag, M., Paradise, S., Grutzendler, J., De Camilli, P., Ferguson, S.M., Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer's disease amyloid plaques. Proc. Nat. Acad. Sci. U. S. A. 112 (2015), E3699–E3708.
316. Wolfe, D.M., Lee, J.H., Kumar, A., Lee, S., Orenstein, S.J., Nixon, R.A., Autophagy failure in Alzheimer's disease and the role of defective lysosomal acidification. Eur. J. Neurosci. 37 (2013), 1949–1961.
317. Asano, T., Komatsu, M., Yamaguchi-Iwai, Y., Ishikawa, F., Mizushima, N., Iwai, K., Distinct mechanisms of ferritin delivery to lysosomes in iron-depleted and iron-replete cells. Mol. Cell. Biol. 31 (2011), 2040–2052.
318. Mancias, J.D., Pontano Vaites, L., Nissim, S., Biancur, D.E., Kim, A.J., Wang, X., Liu, Y., Goessling, W., Kimmelman, A.C., Harper, J.W., Ferritinophagy via NCOA4 is required for erythropoiesis and is regulated by iron dependent HERC2-mediated proteolysis. eLife, 4, 2015.
319. Kurz, T., Terman, A., Gustafsson, B., Brunk, U.T., Lysosomes in iron metabolism, ageing and apoptosis. Histochem. Cell Biol. 129 (2008), 389–406.
320. Hooper, C., Meimaridou, E., Tavassoli, M., Melino, G., Lovestone, S., Killick, R., p53 is upregulated in Alzheimer's disease and induces tau phosphorylation in HEK293a cells. Neurosci. Lett. 418 (2007), 34–37.
321. Morrison, R.S., Kinoshita, Y., The role of p53 in neuronal cell death. Cell Death Different., 7, 2000, 868.
322. Stanga, S., Lanni, C., Govoni, S., Uberti, D., D'Orazi, G., Racchi, M., Unfolded p53 in the pathogenesis of Alzheimer's disease: is HIPK2 the link?. Aging (Albany NY) 2 (2010), 545–554.
323. Cenini, G., Sultana, R., Memo, M., Butterfield, D.A., Elevated levels of pro-apoptotic p53 and its oxidative modification by the lipid peroxidation product, HNE, in brain from subjects with amnestic mild cognitive impairment and Alzheimer's disease. J. Cell Mol. Med. 12 (2008), 987–994.
324. Murphy, M.E., Ironing out how p53 regulates ferroptosis. Proc. Nat. Acad. Sci. U. S. A. 113 (2016), 12350–12352.
325. Gibson, G.E., Shi, Q., A mitocentric view of Alzheimer's disease suggests multi-faceted treatments. J. Alzheimers Dis. 20:Suppl. 2 (2010), S591–607.
326. Cardoso, S.M., Proenca, M.T., Santos, S., Santana, I., Oliveira, C.R., Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiol. Aging 25 (2004), 105–110.
327. Mancuso, M., Filosto, M., Bosetti, F., Ceravolo, R., Rocchi, A., Tognoni, G., Manca, M.L., Solaini, G., Siciliano, G., Murri, L., Decreased platelet cytochrome c oxidase activity is accompanied by increased blood lactate concentration during exercise in patients with Alzheimer disease. Exp. Neurol. 182 (2003), 421–426.
328. Wilkins, H.M., Weidling, I.W., Ji, Y., Swerdlow, R.H., Mitochondria-derived damage-associated molecular patterns in neurodegeneration. Front. Immunol., 8, 2017, 508.
329. Cai, Q., Tammineni, P., Alterations in mitochondrial quality control in Alzheimer's disease. Front. Cell. Neurosci., 10, 2016, 24.
330. Swerdlow, R.H., Burns, J.M., Khan, S.M., The Alzheimer's disease mitochondrial cascade hypothesis. J. Alzheimers Dis. 20:Suppl 2 (2010), S265–279.
331. Chen, H., Chan, D.C., Mitochondrial dynamics–fusion, fission, movement, and mitophagy–in neurodegenerative diseases. Human Mol. Genet. 18 (2009), R169–R176.
332. Sheng, Z.H., Cai, Q., Mitochondrial transport in neurons: impact on synaptic homeostasis and neurodegeneration. Nat. Rev. Neurosci. 13 (2012), 77–93.
333. Ulla, M., Bonny, J.M., Ouchchane, L., Rieu, I., Claise, B., Durif, F., Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up. PloS One, 8, 2013, e57904.
334. Barbosa, J.H., Santos, A.C., Tumas, V., Liu, M., Zheng, W., Haacke, E.M., Salmon, C.E., Quantifying brain iron deposition in patients with Parkinson's disease using quantitative susceptibility mapping, R2 and R2. Magn. Reson. Imaging 33 (2015), 559–565.
335. Du, G., Liu, T., Lewis, M.M., Kong, L., Wang, Y., Connor, J., Mailman, R.B., Huang, X., Quantitative susceptibility mapping of the midbrain in Parkinson's disease. Movement disorders 31 (2016), 317–324.
336. Wieler, M., Gee, M., Martin, W.R., Longitudinal midbrain changes in early Parkinson's disease: iron content estimated from R2**/MRI. Parkinsonism Relat. Disord. 21 (2015), 179–183.
337. Wieler, M., Gee, M., Camicioli, R., Martin, W.R., Freezing of gait in early Parkinson's disease: nigral iron content estimated from magnetic resonance imaging. J. Neurol. Sci. 361 (2016), 87–91.
338. He, N., Ling, H., Ding, B., Huang, J., Zhang, Y., Zhang, Z., Liu, C., Chen, K., Yan, F., Region-specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping. Human Brain Mapping 36 (2015), 4407–4420.
339. Langkammer, C., Pirpamer, L., Seiler, S., Deistung, A., Schweser, F., Franthal, S., Homayoon, N., Katschnig-Winter, P., Koegl-Wallner, M., Pendl, T., Stoegerer, E.M., Wenzel, K., Fazekas, F., Ropele, S., Reichenbach, J.R., Schmidt, R., Schwingenschuh, P., Quantitative susceptibility mapping in Parkinson's disease. PloS One, 11, 2016, e0162460.
340. Rhodes, S.L., Buchanan, D.D., Ahmed, I., Taylor, K.D., Loriot, M.A., Sinsheimer, J.S., Bronstein, J.M., Elbaz, A., Mellick, G.D., Rotter, J.I., Ritz, B., Pooled analysis of iron-related genes in Parkinson's disease: association with transferrin. Neurobiol. Dis. 62 (2014), 172–178.
341. Xia, J., Xu, H., Jiang, H., Xie, J., The association between the C282Y and H63D polymorphisms of HFE gene and the risk of Parkinson's disease: A meta-analysis. Neurosci. Lett. 595 (2015), 99–103.
342. Mann, V.M., Cooper, J.M., Daniel, S.E., Srai, K., Jenner, P., Marsden, C.D., Schapira, A.H., Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Annal. Neurol. 36 (1994), 876–881.
343. Faucheux, B.A., Martin, M.-E., Beaumont, C., Hunot, S., Hauw, J.-J., Agid, Y., Hirsch, E.C., Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. J. Neurochem. 83 (2002), 320–330.
344. Mastroberardino, P.G., Hoffman, E.K., Horowitz, M.P., Betarbet, R., Taylor, G., Cheng, D., Na, H.M., Gutekunst, C.A., Gearing, M., Trojanowski, J.Q., Anderson, M., Chu, C.T., Peng, J., Greenamyre, J.T., A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease. Neurobiol. Dis. 34 (2009), 417–431.
345. Ayton, S., Lei, P., Duce, J.A., Wong, B.X., Sedjahtera, A., Adlard, P.A., Bush, A.I., Finkelstein, D.I., Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease. Annal. Neurol. 73 (2013), 554–559.
346. Boll, M.C., Sotelo, J., Otero, E., Alcaraz-Zubeldia, M., Rios, C., Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease. Neurosci. Lett. 265 (1999), 155–158.
347. Pichler, I., Del Greco, M.F., Gögele, M., Lill, C.M., Bertram, L., Do, C.B., Eriksson, N., Foroud, T., Myers, R.H., Consortium, P.G., Nalls, M., Keller, M.F., International Parkinson's Disease Genomics, C, Wellcome Trust Case Control, C, Benyamin, B., Whitfield, J.B., Genetics of Iron Status, C, Pramstaller, P.P., Hicks, A.A., Thompson, J.R., Minelli, C., Serum iron levels and the risk of Parkinson disease: a mendelian randomization study. PLoS Med., 10, 2013, e1001462.
348. Walter, U., Witt, R., Wolters, A., Wittstock, M., Benecke, R., Substantia nigra echogenicity in Parkinson's disease: relation to serum iron and C-reactive protein. J. Neural Transm. (Vienna, Austria : 1996) 119 (2012), 53–57.
349. Jin, L., Wang, J., Zhao, L., Jin, H., Fei, G., Zhang, Y., Zeng, M., Zhong, C., Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. Brain 134 (2011), 50–58.
350. Abbott, S.K., Jenner, A.M., Spiro, A.S., Batterham, M., Halliday, G.M., Garner, B., Fatty acid composition of the anterior cingulate cortex indicates a high susceptibility to lipid peroxidation in Parkinson's disease. J. Parkinson's Dis. 5 (2015), 175–185.
351. Farooqui, T., Farooqui, A.A., Lipid-mediated oxidative stress and inflammation in the pathogenesis of Parkinson's disease. Parkinson's Dis.(2011), 2011.
352. Shichiri, M., The role of lipid peroxidation in neurological disorders. J. Clin. Biochem. Nutr. 54 (2014), 151–160.
353. Dias, V., Junn, E., Mouradian, M.M., The role of oxidative stress in Parkinson's disease. J. Parkinson's Dis. 3 (2013), 461–491.
354. Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E.R., Mizuno, Y., Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Nat. Acad. Sci. U. S. A., 93, 1996.
355. Fessel, J.P., Hulette, C., Powell, S., Roberts, L.J., Zhang, J., Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease. J. Neurochem. 85 (2003), 645–650.
356. Shamoto-Nagai, M., Maruyama, W., Hashizume, Y., Yoshida, M., Osawa, T., Riederer, P., Naoi, M., In parkinsonian substantia nigra, α-synuclein is modified by acrolein, a lipid-peroxidation product, and accumulates in the dopamine neurons with inhibition of proteasome activity. J. Neural Trans. 114 (2007), 1559–1567.
357. Boll, M.-C., Alcaraz-Zubeldia, M., Montes, S., Rios, C., Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO x content in the CSF. A different marker profile in four neurodegenerative diseases. Neurochem. Res. 33 (2008), 1717–1723.
358. Selley, M.L., (E)-4-Hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. Free Radical Biol. Med. 25 (1998), 169–174.
359. Ilic, T.V., Jovanovic, M., Jovicic, A., Tomovic, M., Indices of oxidative stress in the peripheral blood of de novo patients with Parkinson's disease. Advances in Behavioral Biology, 1998, Springer, US, 779–785.
360. Chen, C.-M., Liu, J.-L., Wu, Y.-R., Chen, Y.-C., Cheng, H.-S., Cheng, M.-L., Chiu, D.T.-Y., Increased oxidative damage in peripheral blood correlates with severity of Parkinson's disease. Neurobiol. Dis. 33 (2009), 429–435.
361. Sanyal, J., Bandyopadhyay, S.K., Banerjee, T.K., Mukherjee, S.C., Chakraborty, D.P., Ray, B.C., Rao, V.R., Plasma levels of lipid peroxides in patients with Parkinson's disease. Eur. Rev. Med. Pharmacol. Sci. 13 (2009), 129–132.
362. Seet, R.C., Lee, C.Y., Lim, E.C., Tan, J.J., Quek, A.M., Chong, W.L., Looi, W.F., Huang, S.H., Wang, H., Chan, Y.H., Halliwell, B., Oxidative damage in Parkinson disease: measurement using accurate biomarkers. Free Radical Biol. Med. 48 (2010), 560–566.
363. Chahine, L.M., Stern, M.B., Chen-Plotkin, A., Blood-based biomarkers for’ s disease. Parkinsonism Related Disord. 20 (2014), S99–S103.
364. Pearce, R.K., Owen, A., Daniel, S., Jenner, P., Marsden, C.D., Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J. Neural Transmission (Vienna, Austria : 1996) 104 (1997), 661–677.
365. Sian, J., Dexter, D.T., Lees, A.J., Daniel, S., Agid, Y., Javoy-Agid, F., Jenner, P., Marsden, C.D., Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Annal. Neurol. 36 (1994), 348–355.
366. Shi, M., Bradner, J., Bammler, T.K., Eaton, D.L., Zhang, J., Ye, Z., Wilson, A.M., Montine, T.J., Pan, C., Zhang, J., Identification of glutathione S-transferase pi as a protein involved in Parkinson disease progression. Am. J. Pathol. 175 (2009), 54–65.
367. Werner, C.J., Heyny-von Haussen, R., Mall, G., Wolf, S., Proteome analysis of human substantia nigra in Parkinson's disease. Proteome Sci., 6, 2008, 8.
368. Maarouf, C.L., Beach, T.G., Adler, C.H., Shill, H.A., Sabbagh, M.N., Wu, T., Walker, D.G., Kokjohn, T.A., Roher, A.E., Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects. Neurol. Res. 34 (2012), 669–676.
369. Smeyne, M., Boyd, J., Raviie Shepherd, K., Jiao, Y., Pond, B.B., Hatler, M., Wolf, R., Henderson, C., Smeyne, R.J., GSTpi expression mediates dopaminergic neuron sensitivity in experimental parkinsonism. Proc. Nat. Acad. Sci. U. S. A. 104 (2007), 1977–1982.
370. Smeyne, M., Smeyne, R.J., Glutathione metabolism and Parkinson's disease. Free Radical Biol. Med. 62 (2013), 13–25.
371. García, J.C., Cruz, R., Leiva, A., Álvarez, P., Soto, Y., McPherson, M., Lesion of the nigrostriatal neurons by 6-hydroxydopamine induces changes in rat brain glutathione-S-transferase. Mol. Chem. Neuropathol. 31 (1997), 149–159.
372. Bellinger, F.P., Raman, A.V., Rueli, R.H., Bellinger, M.T., Dewing, A.S., Seale, L.A., Andres, M.A., Uyehara-Lock, J.H., White, L.R., Ross, G.W., Berry, M.J., Changes in selenoprotein P in substantia nigra and putamen in Parkinson's disease. J. Parkinson's Dis. 2 (2012), 115–126.
373. Castro-Caldas, M., Carvalho, A.N., Rodrigues, E., Henderson, C., Wolf, C.R., Gama, M.J., Glutathione S-transferase pi mediates MPTP-induced c-Jun N-terminal kinase activation in the nigrostriatal pathway. Molecular neurobiology 45 (2012), 466–477.
374. Cho, S.G., Lee, Y.H., Park, H.S., Ryoo, K., Kang, K.W., Park, J., Eom, S.J., Kim, M.J., Chang, T.S., Choi, S.Y., Shim, J., Kim, Y., Dong, M.S., Lee, M.J., Kim, S.G., Ichijo, H., Choi, E.J., Glutathione S-transferase mu modulates the stress-activated signals by suppressing apoptosis signal-regulating kinase 1. J. Biol. Chem. 276 (2001), 12749–12755.
375. Morris, G., Walker, A.J., Berk, M., Maes, M., Puri, B.K., Cell death pathways: a novel therapeutic approach for neuroscientists. Mol. Neurobiol., 2017.
376. Bellinger, F.P., Bellinger, M.T., Seale, L.A., Takemoto, A.S., Raman, A.V., Miki, T., Manning-Bog, A.B., Berry, M.J., White, L.R., Ross, G.W., Glutathione peroxidase 4 is associated with neuromelanin in substantia Nigra and Dystrophic Axons in Putamen of Parkinson's brain. Mol. Neurodegener., 6, 2011, 8.
377. Blackinton, J., Kumaran, R., van der Brug, M.P., Ahmad, R., Olson, L., Galter, D., Lees, A., Bandopadhyay, R., Cookson, M.R., Post-transcriptional regulation of mRNA associated with DJ-1 in sporadic Parkinson disease. Neurosci. Lett. 452 (2009), 8–11.
378. Pillai, R., Uyehara-Lock, J.H., Bellinger, F.P., Selenium and selenoprotein function in brain disorders. IUBMB Life 66 (2014), 229–239.
379. Zucca, F.A., Segura-Aguilar, J., Ferrari, E., Munoz, P., Paris, I., Sulzer, D., Sarna, T., Casella, L., Zecca, L., Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease. Progress Neurobiol. 155 (2017), 96–119.
380. Todorovic, M., Wood, S.A., Mellick, G.D., Nrf2: a modulator of Parkinson's disease?. J. Neural Trans. (Vienna, Austria : 1996) 123 (2016), 611–619.
381. Todorovic, M., Newman, J.R., Shan, J., Bentley, S., Wood, S.A., Silburn, P.A., Mellick, G.D., Comprehensive assessment of genetic sequence variants in the antioxidant ‘master regulator’ NRF2 in idiopathic Parkinson's disease. PloS One, 10, 2015, e0128030.
382. von Otter, M., Bergstrom, P., Quattrone, A., De Marco, E.V., Annesi, G., Soderkvist, P., Wettinger, S.B., Drozdzik, M., Bialecka, M., Nissbrandt, H., Klein, C., Nilsson, M., Hammarsten, O., Nilsson, S., Zetterberg, H., Genetic associations of Nrf2-encoding NFE2L2 variants with Parkinson's disease - a multicenter study. BMC Med. Genet., 15, 2014, 131.
383. Bonifati, V., Rizzu, P., van Baren, M.J., Schaap, O., Breedveld, G.J., Krieger, E., Dekker, M.C., Squitieri, F., Ibanez, P., Joosse, M., van Dongen, J.W., Vanacore, N., van Swieten, J.C., Brice, A., Meco, G., van Duijn, C.M., Oostra, B.A., Heutink, P., Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science (New York, N.Y.) 299 (2003), 256–259.
384. Chen, J., Li, L., Chin, L.-S., Parkinson disease protein DJ-1 converts from a zymogen to a protease by carboxyl-terminal cleavage. Human Mol. Genet. 19 (2010), 2395–2408.
385. Brownell, S.E., Becker, R.A., Steinman, L., The protective and therapeutic function of small heat shock proteins in neurological diseases. Front. Immunol., 3, 2012, 74.
386. Renkawek, K., Stege, G.J., Bosman, G.J., Dementia, gliosis and expression of the small heat shock proteins hsp27 and alpha B-crystallin in Parkinson's disease. Neuroreport 10 (1999), 2273–2276.
387. Belarbi, K., Cuvelier, E., Destée, A., Gressier, B., Chartier-Harlin, M.-C., NADPH oxidases in Parkinson's disease: a systematic review. Mol. Neurodegener., 12, 2017, 84.
388. Alves da Costa, C., Checler, F., Apoptosis in Parkinson's disease: is p53 the missing link between genetic and sporadic Parkinsonism?. Cell. Signal. 23 (2011), 963–968.
389. Dehay, B., Martinez-Vicente, M., Caldwell, G.A., Caldwell, K.A., Yue, Z., Cookson, M.R., Klein, C., Vila, M., Bezard, E., Lysosomal impairment in Parkinson's disease. Mov. Disord. 28 (2013), 725–732.
390. Jiang, P., Gan, M., Yen, S.H., McLean, P.J., Dickson, D.W., Impaired endo-lysosomal membrane integrity accelerates the seeding progression of alpha-synuclein aggregates. Sci. Rep., 7, 2017, 7690.
391. Bourdenx, M., Dehay, B., What lysosomes actually tell us about Parkinson's disease?. Ageing Res. Rev. 32 (2016), 140–149.
392. Lynch-Day, M.A., Mao, K., Wang, K., Zhao, M., Klionsky, D.J., The role of autophagy in Parkinson's disease. Cold Spring Harb. Perspect. Med., 2, 2012, a009357.
393. Krenn, M.A., Schurz, M., Teufl, B., Uchida, K., Eckl, P.M., Bresgen, N., Ferritin-stimulated lipid peroxidation, lysosomal leak, and macroautophagy promote lysosomal “metastability” in primary hepatocytes determining in vitro cell survival. Free Radical Biol. Med. 80 (2015), 48–58.
394. Terman, A., Kurz, T., Lysosomal iron, iron chelation, and cell death. Antioxid. Redox Signal. 18 (2013), 888–898.
395. Keeney, P.M., Xie, J., Capaldi, R.A., Bennett, J.P., Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J. Neurosci. 26 (2006), 5256–5264.
396. Gao, F., Yang, J., Wang, D., Li, C., Fu, Y., Wang, H., He, W., Zhang, J., Mitophagy in Parkinson's disease: pathogenic and therapeutic implications. Front. Neurol., 8, 2017, 527.
397. Deas, E., Wood, N.W., Plun-Favreau, H., Mitophagy and Parkinson's disease: the PINK1–parkin link. Biochim. Biophys. Acta 1813 (2011), 623–633.
398. Truban, D., Hou, X., Caulfield, T.R., Fiesel, F.C., Springer, W., PINK1, Parkin, and mitochondrial quality control: what can we learn about Parkinson's disease pathobiology?. Journal of Parkinson's disease 7 (2017), 13–29.
399. Senft, D., Ronai, Z.A., UPR, autophagy, and mitochondria crosstalk underlies the ER stress response. Trends in biochemical sciences 40 (2015), 141–148.
400. Xiong, H., Wang, D., Chen, L., Choo, Y.S., Ma, H., Tang, C., Xia, K., Jiang, W., Ronai, Z., Zhuang, X., Zhang, Z., Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. The Journal of clinical investigation 119 (2009), 650–660.
401. Gao, H., Yang, W., Qi, Z., Lu, L., Duan, C., Zhao, C., Yang, H., DJ-1 protects dopaminergic neurons against rotenone-induced apoptosis by enhancing ERK-dependent mitophagy. J. Mol. Biol. 423 (2012), 232–248.
402. Krebiehl, G., Ruckerbauer, S., Burbulla, L.F., Kieper, N., Maurer, B., Waak, J., Wolburg, H., Gizatullina, Z., Gellerich, F.N., Woitalla, D., Riess, O., Kahle, P.J., Proikas-Cezanne, T., Kruger, R., Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson's disease-associated protein DJ-1. PloS One, 5, 2010, e9367.
403. Varela-Lopez, A., Giampieri, F., Battino, M., Quiles, J.L., Coenzyme Q and its role in the dietary therapy against aging. Molecules (Basel, Switzerland), 21, 2016, 373.
404. Morris, G., Anderson, G., Berk, M., Maes, M., Coenzyme Q10 depletion in medical and neuropsychiatric disorders: potential repercussions and therapeutic implications. Molecular neurobiology 48 (2013), 883–903.
405. Bello, R.I., Kagan, V.E., Tyurin, V., Navarro, F., Alcain, F.J., Villalba, J.M., Regeneration of lipophilic antioxidants by NAD(P)H:quinone oxidoreductase 1. Protoplasma 221 (2003), 129–135.
406. Navas, P., Villalba, J.M., de Cabo, R., The importance of plasma membrane coenzyme Q in aging and stress responses. Mitochondrion(Suppl. 7), 2007, S34–S40.
407. Littarru, G.P., Tiano, L., Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Molecular biotechnology 37 (2007), 31–37.
408. Quiles, J.L., Pamplona, R., Ramirez-Tortosa, M.C., Naudi, A., Portero-Otin, M., Araujo-Nepomuceno, E., Lopez-Frias, M., Battino, M., Ochoa, J.J., Coenzyme Q addition to an n-6 PUFA-rich diet resembles benefits on age-related mitochondrial DNA deletion and oxidative stress of a MUFA-rich diet in rat heart. Mech. Ageing Dev. 131 (2010), 38–47.
409. Barbiroli, B., Frassineti, C., Martinelli, P., Iotti, S., Lodi, R., Cortelli, P., Montagna, P., Coenzyme Q10 improves mitochondrial respiration in patients with mitochondrial cytopathies. An in vivo study on brain and skeletal muscle by phosphorous magnetic resonance spectroscopy. Cell Mol. Biol. (Noisy-le-grand) 43 (1997), 741–749.
410. Matthews, R.T., Yang, L., Browne, S., Baik, M., Beal, M.F., Coenzyme Q(10) administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Nat. Acad. Sci. U. S. A. 95 (1998), 8892–8897.
411. Ishrat, T., Khan, M.B., Hoda, M.N., Yousuf, S., Ahmad, M., Ansari, M.A., Ahmad, A.S., Islam, F., Coenzyme Q10 modulates cognitive impairment against intracerebroventricular injection of streptozotocin in rats. Behav. Brain Res. 171 (2006), 9–16.
412. Kim, D.W., Hwang, I.K., Kim, D.W., Yoo, K.Y., Won, C.K., Moon, W.K., Won, M.H., Coenzyme Q_{10} effects on manganese superoxide dismutase and glutathione peroxidase in the hairless mouse skin induced by ultraviolet B irradiation. BioFactors (Oxford, England) 30 (2007), 139–147.
413. Rauscher, F.M., Sanders, R.A., Watkins, J.B. 3rd, Effects of coenzyme Q10 treatment on antioxidant pathways in normal and streptozotocin-induced diabetic rats. J. Biochem. Mol. Toxicol. 15 (2001), 41–46.
414. Gerwyn, M., Maes, M., Mechanisms explaining muscle fatigue and muscle pain in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a review of recent findings. Curr. Rheumatol. Rep., 19, 2017, 1.
415. Morris, G., Berk, M., Galecki, P., Walder, K., Maes, M., The neuro-immune pathophysiology of Central and peripheral fatigue in systemic immune-inflammatory and neuro-immune diseases. Mol. Neurobiol. 53 (2015), 1195–1219.
416. Grolez, G., Moreau, C., Sablonniere, B., Garcon, G., Devedjian, J.C., Meguig, S., Gele, P., Delmaire, C., Bordet, R., Defebvre, L., Cabantchik, I.Z., Devos, D., Ceruloplasmin activity and iron chelation treatment of patients with Parkinson's disease. BMC Neurol., 15, 2015.
417. Kuo, K.H., Mrkobrada, M., A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with beta-thalassemia. Hemoglobin 38 (2014), 409–421.
418. Sripetchwandee, J., Pipatpiboon, N., Chattipakorn, N., Chattipakorn, S., Combined therapy of iron chelator and antioxidant completely restores brain dysfunction induced by iron toxicity. PloS One, 9, 2014, e85115.
419. Sripetchwandee, J., Wongjaikam, S., Krintratun, W., Chattipakorn, N., Chattipakorn, S.C., A combination of an iron chelator with an antioxidant effectively diminishes the dendritic loss, tau-hyperphosphorylation, amyloids-beta accumulation and brain mitochondrial dynamic disruption in rats with chronic iron-overload. Neuroscience 332 (2016), 191–202.
420. Wongjaikam, S., Kumfu, S., Khamseekaew, J., Sripetchwandee, J., Srichairatanakool, S., Fucharoen, S., Chattipakorn, S.C., Chattipakorn, N., Combined iron chelator and antioxidant exerted greater efficacy on cardioprotection than monotherapy in iron-overloaded rats. PloS One, 11, 2016, e0159414.
421. Caglikulekci, M., Dirlik, M., Pata, C., Plasse, M., Tamer, L., Ogetman, Z., Ercan, B., Effect of N-acetylcysteine on blood and tissue lipid peroxidation in lipopolysaccharide-induced obstructive jaundice. J. Invest. Surg. 19 (2006), 175–184.
422. Wright, D.J., Renoir, T., Smith, Z.M., Frazier, A.E., Francis, P.S., Thorburn, D.R., McGee, S.L., Hannan, A.J., Gray, L.J., N-acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease. Transl. Psychiatry, 5, 2015, e492.
423. De Benedetto, F., Aceto, A., Dragani, B., Spacone, A., Formisano, S., Pela, R., Donner, C.F., Sanguinetti, C.M., Long-term oral n-acetylcysteine reduces exhaled hydrogen peroxide in stable COPD. Pulm Pharmacol. Ther. 18 (2005), 41–47.
424. Berk, M., Malhi, G.S., Gray, L.J., Dean, O.M., The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol. Sci. 34 (2013), 167–177.
425. Dean, O., Giorlando, F., Berk, M., N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J. Psychiatry Neurosci. 36 (2011), 78–86.
426. Minarini, A., Ferrari, S., Galletti, M., Giambalvo, N., Perrone, D., Rioli, G., Galeazzi, G.M., N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects. Expert Opin. Drug Metab. Toxicol. 13 (2017), 279–292.
427. Moos, T., Nielsen, T.R., Ferroportin in the Postnatal Rat Brain: Implications for Axonal Transport and Neuronal Export of Iron, Seminars in Pediatric Neurology. 2006, Elsevier, 149–157.
428. Yang, W.S., Stockwell, B.R., Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 26 (2016), 165–176.
429. Baldeiras, I., Santana, I., Proenca, M.T., Garrucho, M.H., Pascoal, R., Rodrigues, A., Duro, D., Oliveira, C.R., Peripheral oxidative damage in mild cognitive impairment and mild Alzheimer's disease. J. Alzheimers Dis. 15 (2008), 117–128.